

Journal of Visualized Experiments

A deep-sequencing-assisted, spontaneous suppressor screen in the fission yeast *Schizosaccharomyces pombe* --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59133R2
Full Title:	A deep-sequencing-assisted, spontaneous suppressor screen in the fission yeast <i>Schizosaccharomyces pombe</i>
Keywords:	Suppressor mutation, genetic interaction, spontaneous phenotypic recovery, whole-genome sequencing, bioinformatics analysis, fission yeast
Corresponding Author:	Ke Zhang UNITED STATES
Corresponding Author's Institution:	
Corresponding Author E-Mail:	zhangk@wfu.edu
Order of Authors:	Bahjat F. Marayati James B. Pease Ke Zhang
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Winston Salem

TITLE:

A Deep-Sequencing-Assisted, Spontaneous Suppressor Screen in the Fission Yeast *Schizosaccharomyces pombe*

AUTHORS & AFFILIATIONS:

Bahjat F. Marayati^{1,2}, James B. Pease¹, Ke Zhang^{1,2}

¹Department of Biology, Wake Forest University, Winston-Salem, NC

²Center for Molecular Communication and Signaling, Wake Forest University, Winston-Salem, NC

Corresponding Author:

Ke Zhang, Ph.D. (zhangk@wfu.edu)

Email Addresses of Co-Authors:

Bahjat F. Marayati (marab15@wfu.edu)

James B. Pease (peasejb@wfu.edu)

KEYWORDS:

suppressor mutation, genetic interaction, spontaneous phenotypic recovery, whole-genome sequencing, bioinformatics analysis, fission yeast

SUMMARY:

We present a simple suppressor screen protocol in fission yeast. This method is efficient, mutagen-free, and selective for mutations that often occur at a single genomic locus. The protocol is suitable for isolating suppressors that alleviate growth defects in liquid culture that are caused by a mutation or a drug.

ABSTRACT:

A genetic screen for mutant alleles that suppress phenotypic defects caused by a mutation is a powerful approach to identify genes that belong to closely related biochemical pathways. Previous methods such as the Synthetic Genetic Array (SGA) analysis, and random mutagenesis techniques using ultraviolet (UV) or chemicals like ethyl methanesulfonate (EMS) or N-ethyl-N-nitrosourea (ENU), have been widely used but are often costly and laborious. Also, these mutagen-based screening methods are frequently associated with severe side effects on the organism, inducing multiple mutations that add to the complexity of isolating the suppressors. Here, we present a simple and effective protocol to identify suppressor mutations in mutants which confer a growth defect in *Schizosaccharomyces pombe*. The fitness of cells with a growth deficiency in standard rich liquid media or synthetic liquid media can be monitored for recovery using an automated 96-well plate reader over an extended period. Once a cell acquires a suppressor mutation in the culture, its descendants outcompete those of the parental cells. The recovered cells that have a competitive growth advantage over the parental cells can then be isolated and backcrossed with the parental cells. The suppressor mutations are then identified using whole-genome sequencing. Using this approach, we have successfully isolated multiple suppressors that alleviate the severe growth defects caused by loss of Elf1, an AAA+ family ATPase that is important in nuclear mRNA transport and maintenance of genomic stability. There

are currently over 400 genes in *S. pombe* with mutants conferring a growth defect. As many of these genes are uncharacterized, we propose that our method will hasten the identification of novel functional interactions with this user-friendly, high-throughput approach.

INTRODUCTION:

The basis of understanding functional links between genes relies on the ability to identify the molecular mechanism(s) by which complex genetic traits diverge to produce diverse phenotypes¹. In the fission yeast, *Schizosaccharomyces pombe* (*S. pombe*), the majority of protein-coding genes are dispensable for viability². This result does not speak to the unimportance of these genes, but rather to the intricate compensatory mechanisms underlying the biochemical pathways to which such genes belong. Dissecting these compensatory mechanisms has generated epistasis maps, which have uncovered comprehensive genetic interactions and broadened our understanding of functional biochemical pathways^{3,4}.

High-throughput methods (e.g., Synthetic Genetic Array analysis, or SGA) have been developed to identify genome-wide genetic interactions in budding yeast, and have been expanded for use in fission yeast^{5,6}. Such approaches often rely on a library of strains containing all viable single protein-coding gene deletions (around 3,300 haploid deletion mutants covering over 92% of the fission yeast genome), and require a robotic arm to perform the genetic crosses between the strain of interest and all possible strains in the library⁶. Further, SGA techniques depend on the ability of library strains to have proper and efficient mating, a phenotype that is abnormal to 444 currently characterized genes in *S. pombe*².

Despite the complexity of genetic interactions, comparing the phenotype of a strain carrying mutations in two genes to the phenotype of two strains carrying individual mutations of each gene can have one of two notable outcomes: 1) The double mutant phenotype is worse than the expected multiplicative parental phenotypes in the form of sickness or, in the most extreme case, lethality. This is referred to as a negative genetic interaction, and is generally a sign that the two genes act in parallel biological pathways. 2) The double mutant phenotype is better than the expected combination of parental phenotypes, also known as a positive genetic interaction. A positive genetic interaction is particularly interesting because it indicates that these genes function in the same process. Two positively interacting genes have three potential relationships: a mutant gene may up-regulate the expression of the other gene in a parallel pathway, the two genes may work in concert within the same pathway downstream of one another, or the two genes encode proteins that interact directly with each other. Therefore, positive genetic interactions can be used to map gene regulatory nodes and classify uncharacterized genes in biochemical pathways^{7,8}.

A suppressor is a mutation that can alleviate the sickness phenotype of the mutation of another gene, typically representing a positive genetic interaction between the two genes^{9,10}. Suppressor mutations on a different locus from that of the mutation they suppress are known as extragenic suppressors. They are especially valuable in studying non-viable genetic mutations by synthetically rescuing the lethal phenotype (also known as the Lazarus effect)¹¹. They also have potential therapeutic applications in treating hereditary diseases^{12,13}.

For all of these reasons, the identification of suppressor mutations in various model organisms has been widely utilized to facilitate our understanding of various biochemical pathways^{14–16}. Screening for suppressors is usually based on the phenotype of the mutation in question and requires conducting random mutagenesis to isolate the mutations that would alleviate the phenotype. Almost all model organisms have established random mutagenesis methods. For example, N-ethyl-N-nitrosourea (ENU) and ethylmethanesulfonate (EMS), two mutagens that are capable of inducing point mutations in DNA, are widely employed in various models from bacteria to mice^{17–19}. In addition, manganese chloride has long been used in yeasts for the ability of the manganese cation to inhibit DNA repair pathways²⁰. Another common approach is UV-induced mutagenesis, which generates genome-wide mutagenic pyrimidine dimers^{21,22}.

Although the utilization of chemical mutagenesis to identify suppressor mutations has been popular, the method has many drawbacks, including the use of dangerous chemicals, highly variable success rates, and the introduction of extra confounding variables presented by the negative side effects of the mutagen on multiple cellular processes^{23,24}. Additionally, chemical mutagenesis often induces multiple mutations in the genome which adds to the complexity of using genetic and sequencing techniques to identify the exact mutation that conferred the suppressor phenotype in the organism²⁵.

To address the shortcomings of current mutagenesis approaches, we present a method to screen for spontaneous suppressor mutations in fission yeast that does not rely on any mutagens or a deletion library. The method isolates suppressors through a positive selection assay. The principle of this method is based on the growth advantage of the mutated suppressor subpopulation in the liquid culture, which can be monitored by an automated plate reader. Mating and meiosis are used only if one would like to clean up the genetic background or confirm the presence of monogenic alleles of suppressors before whole-genome sequencing. If the suppression phenotype is caused by a single mutation, the suppressor phenotype will segregate 2:2 after backcrossing with the parental strains. The suppressor mutations can then be identified using whole-genome sequencing. We propose that this method is applicable for screening suppressors in all microorganisms that can grow to a large population in liquid culture.

PROTOCOL:

1. Strain construction and preparation

1.1. Generate a mutation or a deletion of the gene (*yfm*, *your favorite mutation*) using standard site-directed mutagenesis (SDM) as described previously²⁶.

1.2. Before starting the screen, (optimally) backcross the mutant strains with a wild-type strain to clean the genetic background and generate fresh-born mutant cells as the parental strains. Streak the parental strain to individual colonies on standard rich media plates. Randomly pick eight to sixteen independent colonies (biological replicates) with the desired mutations for the plate reader assay (see 3.1).

NOTE: This protocol is effective only when the parental strains have a growth defect in liquid media (minimal or rich, with or without drug, or with temperature shifts that cause the growth defect). All parental strains should be haploid and thus able to be genetically crossed with other haploid strains with a complementary mating type.

2. Plate reader assay

2.1. With a sterile applicator, take a small amount of each of the colonies prepared in step 1.1 (no exact amount necessary to inoculate the starting culture) and place in a 96-well polystyrene microplate. Suspend each of the colonies in 200 μ L of appropriate liquid media (rich or minimal, with or without drug). Include a blank well for every row on the plate containing 200 μ L of the same media (no cells).

2.2. Run the following protocol on a plate reader detection software connected to an automated microplate-reader: Set a kinetic program for 24 h and temperature at 30 $^{\circ}$ C, with continuous fast orbital shaking (425 cpm, 3 mm amplitude). Set the optical reads to measure light scatter at a wavelength of 600nm for optical density, and set the light to read from below the plate at a reading frequency of 2 min (720 total reads over a 24-h period per well).

2.3. After 24 h, record the final blanked optical density readings (blanked OD600) and use the following formula to determine the volume needed to dilute each of the samples down to O.D. = 0.1:

$$\frac{\text{desired final O.D.} \times \text{desired final volume}}{\text{recorded blanked O.D.}} \times \frac{0.1 \times 200}{\text{recorded blanked O.D.}}$$

NOTE: Export the data from the plate reader software and use a spreadsheet software to insert the above formula as a function to batch process the dilution volume to be used from each experimental well.

2.4. Every 24 h, dilute each of the samples using the same media as day 0 to O.D. = 0.1 (about 1.5×10^6 cells/mL) using the formula indicated in step 2.3. Save all growth curves generated daily and note any individual colony that shows an increased growth rate, judged by a final O.D. that is significantly higher than the rest of the cohort with the same genetic background or by a growth curve that is similar to that of wild-type colonies.

NOTE: This assay usually takes about 7-14 days. Perform all steps under sterile conditions.

3. Selection of suppressor colonies and confirmation of phenotype.

3.1. From the last day of the plate reader assay (step 2.4), save the liquid cultures that have a noticeably recovered growth rate, presumably by gaining a suppressor mutation that can alleviate the phenotype of the parental mutation. Transfer and mix 250 μ L liquid culture to a

176 cryotube containing 250 μ L of 50% glycerol. Flash freeze the cells in liquid nitrogen and save the
177 strains in -80°C indefinitely.

178
179 3.2. To confirm that the suppressor mutation is a genetically heritable element, use standard
180 genetic crossing methods to cross *yfm P* (for parental, the strain used at the beginning of the
181 plate reader assay) with *yfm S* (for suppressor, the strain saved at the end of the plate reader
182 assay). If the suppressor mutation is indeed a genetically heritable element, *yfm P* \times *yfm S* should
183 yield tetrads in which two colonies have the sickness phenotype of the parental strain and two
184 colonies have the recovered growth rate of the suppressor strain.

185
186 3.3. From the cross of step 3.2, pick three colonies with the suppressor phenotype (S strain) and
187 three colonies with the parental phenotype (P strain) from the same genetic cross (3 biological
188 replicates for each), and proceed with the genomic DNA extraction and sequencing steps below.

189
190 NOTE: Steps 3.2 and 3.3 are highly recommended, but are not required. Alternatively, one can
191 spread recovered liquid culture collected from 3.1 on rich medium into single colonies, then
192 randomly pick three colonies as biological triplicates for whole-genome sequencing without
193 further genetic confirmation. In this case, three biological triplicates of parental strain should be
194 used for genomic sequencing comparison.

195 196 4. Genomic DNA extraction, library production and sequencing.

197
198 4.1. For DNA extraction, library preparation, and sequencing, randomly pick three biological
199 replicates per *yfm P* strain, and three biological replicates of each individually arisen *yfm S* strains
200 from the genetic crosses (step 3.2) or from the plates that have been spread to obtain single
201 colonies of the S strain (step 3.3 note).

202
203 4.2. Grow strains in 10 mL cultures in rich media to mid-log phase (O.D. = 0.5–0.8, about 0.75×10^7 cells/mL), and use a shaking incubator to grow liquid cultures at 30 °C with continuously
204 shaking at 250 rpm. Collect cells by centrifugation at 4 °C for 5 min at 1000 x *g*.

205
206 4.3. Suspend pelleted cells in 400 μ L of DNA extraction buffer (2% Triton X-100, 1% SDS, 100 mM
207 NaCl, 10 mM Tris-Cl (pH 8.0), 1mM Na₂-EDTA), then add 400 μ L of glass beads and 400 μ L of
208 25:24:1 phenol:chloroform:isoamyl alcohol. Vortex vigorously for 2 min at 4 °C.

209
210 4.4. Add an additional 200 μ L of the DNA extraction buffer and mix by inverting several times.
211 Centrifuge for 5 min at 4 °C at 20,000 x *g*.

212
213 4.5. Transfer the aqueous phase to a clean tube, add 20 μ g of RNase A/T1 mix, and incubate at
214 37 °C for 15 min.

215
216 4.6. Add an equal volume of 25:24:1 phenol:chloroform:isoamyl alcohol, spin for 5 min at 4 °C at
217 20,000 x *g*, then transfer the aqueous phase to a clean tube.

218
219

4.7. Add an equal volume of chloroform, mix by inverting several times, then spin for 5 min at 4 °C at 20,000 x *g*, then transfer the aqueous phase to a clean tube.

4.8. Precipitate DNA with two volumes of 100% ethanol plus 10% volume of 3 M NaOAC (pH 4.3) at -20 °C for at least 2 h, then spin for 5 min at 4 °C at 20,000 x *g* and collect the pellet.

4.9. Wash pellet (precipitated DNA) twice with chilled 70% ethanol (Centrifuge at 20,000 x *g*, 5 min, 4 °C) and suspend the pellet in 50 µL of 10 mM Tris Buffer (pH 7.4).

4.10. Use a library prep kit (see **Table of Materials**) per manufacturer's recommendations to prepare the whole-genome sequencing library.

NOTE: We recommend the kit listed in the **Table of Materials** because it allows the construction of the genomic library without PCR amplification, which minimizes error mutations generated during PCR amplification. In addition, during the genomic library preparation, do not allow the beads to fully dry by shortening the bead drying time to 1–2 min.

4.11. For shearing parameters during the library preparation, use a focused sonicator (see **Table of Materials**) and set the duty factor to 20%, peak power to 175 W, with 200 cycles per burst, and frequency sweeping mode at 5.5°C to 6 °C for 45 s. Alternatively, use a DNA and chromatin shearing system (see **Table of Materials**) with the following settings: 50% amplitude at 4 °C with pulse mode, 15 s on and 15 s off for 10 min, with a total processing time of 20 min.

4.12. It is essential to handle the hazardous materials used in this step with care. Consult the appropriate Material Safety Data Sheets and institution's Environmental Health and Safety Office for handling NaOAC, ethanol, 25:24:1 phenol:chloroform:isoamyl alcohol and chloroform.

4.13. Sequence the resulting genomic libraries. The entire sequencing reads should cover at least three times of the entire genome with the resolution at a single nucleotide range. Paired-ended sequencing (or latest technology) is recommended.

5. Bioinformatics analysis for the identification of the suppressor mutations

5.1. Perform the bioinformatics analysis to focus on the genomic changes that are consistently identified between parental and suppressed *yfm* strains in all biological replicates.

NOTE: The complete pipeline process is described below, but, additionally, two plain-text BASH-script files, `fastq_to_vcf.sh` and `vcfprocess.sh`, are included as supplemental materials to show examples of the workflow from processing of reads to VCF variant files and processing and intersection of the VCF files, respectively.

5.2. Trim short-reads using SHEAR (<https://github.com/jbpease/shear>) following the command lines (all other options default):

```
shear.py --fq1 $FASTQ1 --fq2 $FASTQ2 --out1 $OUTFQ1 --out2 $OUTFQ2 \
```

```
264 --barcodes1 $BARCODE --platform TruSeq --trimqual 20:20 \  
265 --trimpolyat 0 --trimambig --filterlength 50 --filterunpaired
```

266
267 5.3. Map reads to the *S. pombe* reference genome v2.30 obtained from PomBase
268 (ftp://ftp.ebi.ac.uk/pub/databases/pombase/pombe/Chromosome_Dumps/fasta/) using BWA
269 v0.7.15²⁷. Use the following command line (all other options default):

```
270 bwa mem -t 8 $GENOME $OUTFQ1 $OUTFQ2 > $SAM1
```

271
272 5.4. Put alignment SAM files through GATK best practices pipeline²⁸ for variant calling using GATK
273 v3.6²⁹, PicardTools v2.5.0 (<http://broadinstitute.github.io/picard>), and SAMtools v1.3.1³⁰. Use
274 the following command lines and parameters (all other options default):

```
275 java -Xmx30g -jar picard.jar AddOrReplaceReadGroups INPUT=$SAM1 \  
276 OUTPUT=$BAMMARKED RGID=1 RGLB=lib01 RGPL=illumina \  
277 RGPU=$BARCODE RGSM=$SAMPLENUMBER  
278 samtools fixmate -O bam $BAMMARKED $BAMFIXED  
279 samtools sort -O bam -o $BAMSORTED -T /home/peasejb/tmp $BAMFIXED  
280 samtools index $BAMSORTED  
281 java -Xmx30g -jar GenomeAnalysisTK.jar -T HaplotypeCaller \  
282 -R $GENOME -I $BAMSORTED --genotyping_mode DISCOVERY \  
283 -stand_emit_conf 10 -stand_call_conf 30 -o $VCFRAW
```

284
285 5.5. Compress and index VCF files using tabix:

```
286 bgzip $VCFRAW.vcf  
287 tabix $VCFRAW.vcf.gz
```

288
289 5.6. Compare VCF files among parental and suppressor strains sequencing replicates using
290 BCftools v1.3.1²⁷. Use the following command lines and parameters (all other options left
291 default):

```
292 bcftools isec -n+1 $VCFPARENTAL1.gz $VCFPARENTAL2.gz $VCFPARENTAL3.gz \  
293 $VCFMUTANT1.gz $VCFMUTANT2.gz $VCFMUTANT3.gz > common_variants.list
```

294
295 NOTE: This command yielded a file encoded with binary patterns where sequence variants
296 appearing in the first mutant only would be binary-encoded as "000100", the second mutant only
297 as "000010", all three mutants as "000111," etc. These files were generated for each set of
298 parental and mutant replicate VCF files.

299
300 5.7. Compile the variant intersection list files together with the file name appended to each line
301 using the UNIX **grep** command:

```
302 grep "." *.list > all.list
```

303
304 5.8. Cross-reference the complete variant list with the current GFF3 annotation file
305 (ftp://ftp.ebi.ac.uk/pub/databases/pombase/pombe/Chromosome_Dumps/gff3/schizosacchar
306 [omyces_pombe.chr.gff3](ftp://ftp.ebi.ac.uk/pub/databases/pombase/pombe/Chromosome_Dumps/gff3/schizosacchar)) using a custom Python script (variant_characterize.py) to identify

consistent SNP sites in protein-coding regions (synonymous and non-synonymous), 5' and 3' UTRs, and ncRNA.

```
python3 variant_characterize.py --list common_variants.list \  
--gff schizosaccharomyces_pombe.chr.gff3 \  
--fasta Schizosaccharomyces_pombe.ASM294v2.30.dna.genome.fa \  
--pattern 000100 --out all.list.filter.000100
```

Repeat this script modifying the --pattern and the suffix of the output file (--out) using the binary patterns: 000010, 000001, 000110, 000011, 000101, and 000111

5.9. Combine the output from all these script runs in a tab-separated file, to be viewed as a spreadsheet. The annotated table of variants includes those that appear in either one or both mutant strain(s) relative to the background. The binary flag field denotes either appearance in a single mutant strain (000100, 000010, 000001), two mutant strains (000011, 000101, 000110), or all three mutant strains (000111).

5.10. Analyze the output annotated lists of variants not found in the parental samples, but found in one, two, or all three mutant samples. The annotation denotes both the genomic location and class of variant (synonymous/non-synonymous in a coding region, 3'/5' UTR, non-coding, etc.). From this list of candidate mutations, an example of a strongly relevant candidates might be a non-synonymous coding variant appearing consistently in all three strains. Another type of strong candidate would be an accumulation of various non-synonymous or putative regulatory mutations in the mutant strains appearing close together or within the same gene.

REPRESENTATIVE RESULTS:

Slow-growing mutants show phenotypic recovery in liquid culture

We selected three mutants involved in a variety of biological pathways with a sick, slow-growing, phenotype: AAA family ATPase *Elf1*, Histone Deacetylase *Clr6*, and Exon Junction Complex component *Fal1*. A wild-type strain and strains carrying mutations of these three genes that had been backcrossed with wild-type strains were streaked to individual colonies, and 16 single colonies were randomly selected to be cultured in rich liquid media using the 96-well plate as described above. Growth curves of individual colonies were recorded at the initial time point (day 0) and for 6 days with continuous monitoring using the plate reader. As expected, wild-type colonies show no noticeable changes in their growth curves throughout the experiment³¹ (**Figure 1**). Notably, four colonies with the *elf1Δ* background and one *fal1Δ* colony show a dramatic shift in growth from slow-growing to some varying levels of growth similar or close to that of wild-type colonies. Dramatically, all *clr6-1* mutants show a consistent phenotypic recovery, growing at a faster rate by the end of the assay³¹ (**Figure 1**). To characterize the different phenotypes, we refer to the original strains that are slow-growing as “P strains” (or parental strains) and to the strains showing phenotypic recovery as “S strains” (or suppressed strains). Please note that **Figure 1** is an example of one round of the screening experiment, and does not represent the total non-complementary suppressors identified and sequenced in the following representative results.

Phenotypic recovery is attributed to heritable traits

S. pombe can grow as a haploid in rich media, but two haploid strains with complementary mating types mate under nitrogen starvation. Meiosis in fission yeast entails a round of duplication followed by two rounds of cell division. The sexual cycle results in the formation of four haploid spores carrying the genetic material of the parental strain with 2:2 segregation of genetic traits following the rules of classical Mendelian genetics (**Figure 2A**). When grown on the same plate for the same amount of time, we confirmed the 2:2 segregation when back-crossing all suppressed strains (S strains) with their parental strains (P strains), which resulted in 2 small (growth defect) and 2 large (suppressor phenotype) colonies. Individual examples for suppressed *elf1Δ*, *clr6-1* and *fal1Δ* cells are shown in **Figure 2B**. We have confirmed that all isolated S strains carry a monogenic genetic element that suppresses the slow-growing phenotype of their P strains (data not shown).

Whole-genome sequencing successfully identifies suppressor mutations

As an example, we used paired-end whole genome sequencing to identify the genetic elements responsible for the phenotypic recovery in *elf1Δ* S strains. A more complete description of data analysis is available online³¹. Briefly, we employed biological triplicates of two independently generated *elf1Δ* P strains and biological duplicates of five non-complementary groups of *elf1Δ* S strains, each of which contains different suppressors. After we obtained a list of annotated variants from bioinformatics analysis (6.1-10), we prioritized certain classes of variants that were relevant to our analysis. We focused on identification of consistent genomic changes that were identical in all of the biological replicates of individual *elf1Δ* S strains compared with their parental *elf1Δ* P strains (**Figure 3** and **Supplemental Tables 1-4**). We identified five nonsynonymous changes at CDS regions in all five different *elf1Δ* S strains, including *rli1*⁺, *SPBPJ4664.02*, *cue2*⁺ and *rpl2702*⁺. Both S-A1 and S-A2 contain mutated *SPBPJ4664.02*, although the mutations occur at different amino acids. Because *SPBPJ4664.02* is a long gene (11,916 nucleotides) with hundreds of repeats, the mutations were unable to be confirmed by performing PCR followed by sequencing. S-A3 contains a deletion mutant in *rli1* that is consistent in both biological duplicates. However, the mutant did not co-segregate with the S phenotype in *elf1Δ* background. We identified a *cue2* mutant (*cue2-1*) in S-B1, with the amino acids 396-400 missing. S-B2 contains an *rpl2702* mutant (*rpl2702-1*), which changes amino acid at position 45 from Glycine to Aspartate³¹. Both *cue2-1* and *rpl2702-1* were confirmed as *elf1Δ* suppressors as shown below.

Genetic confirmation of identified suppressor mutations verifies the heritability of the recovery phenotype

Two of the identified nonsynonymous changes, *cue2-1* and *rpl2702-1*, were reconstructed in the lab using standard protocols for site-directed mutagenesis. Double mutant strains *cue2-1 elf1Δ* P and *rpl2702-1 elf1Δ* P were crossed with the complimentary *elf1Δ* P strain³¹ (**Figure 4**). If the nonsynonymous mutations, identified through this screen, were sufficient to suppress *elf1Δ* P, then the resulting tetrads would show a 2:2 small to large ratio in the colonies resulting from the 4 spores in each tetrad. Indeed, genetic crossing showed that the identified suppressor mutations are successful in suppressing the slow-growing phenotype of *elf1Δ* P and are heritable.

FIGURE LEGENDS:

Figure 1: Phenotypic recovery can be monitored by recording growth curves in a plate reader. Sixteen single colonies of wild-type (WT), *elf1Δ*, *clr6-1*, and *fal1Δ* were placed in a 96-well plate. Growth curves were recorded over a 24-h period and colonies were re-diluted daily in rich media. The growth defect is evident by the low absorbance (O.D.) at the end of the 24 h period on day 0. Phenotypically recovered strains are those that display a growth curve similar, or close to, that of wild-type over the 24-h period on day 6. Four colonies of *elf1Δ*, one colony of *fal1Δ*, and all colonies of *clr6-1* showed various levels of phenotypic recovery after 6 days.

Figure 2: Genetic crossing can confirm that the phenotypic recovery is attributed to a single heritable allele. (A) When fission yeast cells are subjected to nitrogen starvation, two haploid cells with a complementary mating type can generate a zygote which sporulates to generate a tetrad of 4 spores. The parental genetic materials will segregate during meiosis following the rules of Mendelian genetics. (B) Phenotypically recovered colonies (labeled S, for suppressed) with indicated parental genotypes were back-crossed with their complimentary parental colony (which shows no phenotypic recovery, labeled P, for parental). Genetic crosses showing 2:2 small (poor fitness) to large (recovered fitness) colonies demonstrate that the phenotypic recovery is heritable and can be attributed to a single genetic element. Red boxes are colonies carrying the suppressor allele, and blue boxes are colonies carrying the parental allele. This figure has been modified from Marayati et al., 2018³¹.

Figure 3: Analysis of genome-wide sequencing data to identify genetic elements responsible of phenotypic recovery. Three biological replicates of two parental “P” strains (P-A and P-B), and two biological replicates of five phenotypically recovered switched “S” strains (S-A1, S-A2, and S-A3 recovered from P-A; S-B1 and S-B2 from P-B), were sequenced and the mutations were organized as a list of each mutation in the recovered strain as compared to the parental strain genome it was derived from (e.g., P-A vs. S-A1, etc.). The total number of detected mutations across the entire genome of all such pairwise comparisons was 660. A total of 44 mutations were identified when only mutations that occur in both biological replicates of the same “S” strain were selected. Out of 44 mutations, 12 mutations were insertion/deletion (INDEL) or non-synonymous mutations. Out of the 12 INDEL or non-synonymous mutations, five occurred in the protein coding sequence. The five mutations potentially correlate with the single genetic element responsible for the phenotypically recovered strains: a non-synonymous mutation in *SPBPJ4664.02* found in S-A1 and S-A2, INDEL in *rli1* found in S-A3, INDEL in *cue2* found in S-B1, and non-synonymous mutations in *rpl2702* found in S-B2. Detailed sequence information on the mutations and the filtered background is included in **Supplemental Tables 1-4**.

Figure 4: Confirmation of the suppressors identified through whole-genome sequencing. Results from whole-genome sequencing were confirmed by independently generating the mutations and performing genetic crosses to confirm the phenotypic recovery by crossing an *elf1Δ cue2-1* strain with an *elf1Δ P* strain, and *elf1Δ rpl2702-1* with *elf1Δ P* strain. Three representative vertical tetrads are shown. Red boxes are double-mutant colonies (*elf1 cue2-1*, or

elf1 rpl2702-1); blue boxes are *elf1Δ* colonies. This figure has been modified from Marayati et al., 2018³¹.

DISCUSSION:

The protocol described here represents a novel and simple screen for spontaneous suppressor mutations detectable through phenotypic recovery of mutations conferring slow growth in fission yeast, a phenotype characteristic of over 400 genes in *S. pombe*, the function of many of which remains unknown^{2,32}. Previous methods have taken other approaches to screen for suppressor mutations in microorganisms, including the use of mutagens²¹, or the application of a temperature shift in temperature-sensitive mutant backgrounds³³. In contrast, this protocol shows that phenotypic recovery occurs without additional environmental/chemical interference and highlights the fitness advantage of the rise of suppression mutations eventually taking over the resources available in liquid culture. This screen allows the isolation of both bypass suppressors or interaction suppressors because it is effective for both loss-of-function mutations such as *elf1Δ* or *fal1Δ* and point mutations such as *clr6-1*, as long as the mutants demonstrate fitness defects in liquid culture.

So far, all recovered S strains that we have investigated have demonstrated varying degrees of phenotypic recovery. As detected through genetic crossing, the recovered phenotype is attributable to a single genetic element and is heritable (examples shown in **Figure 2**). This is one of the most significant advantages of this method compared to chemical-based or UV-based suppressor screens, which often target multiple genomic loci. It is common to observe one or two colonies recovered out of 16 colonies/strain (around 10%) within a week. However, we did notice that certain mutants, such as the loss-of-function of Rrp6, the nuclear-specific exosome subunit, never recovered to the almost wild-type growth rate observed in *elf1Δ* cells³¹. It is likely that the function of Rrp6 can only be partially compensated by suppressors, unlike the function of the other mutants tested, including *fal1Δ*, which was shown to cause a severe meiotic defect through its important function in regulatory splicing³⁴. We believe that alternative suppressor screening methods would be subject to the same problem when *yfg* has unique, non-replaceable roles in cell growth.

Before performing genomic sequencing, it is optimal to back-cross the phenotypically recovered colonies, identified from the plate-reader, with the parental strains to clear the genetic background and obtain biological replicates. In addition, deep whole-genome sequencing identifies hundreds of single nucleotide changes, most of which are not identical between biological replicates that are of little interest for the screening. For example, we found a total of 660 genomic alterations across all three chromosomes between the two *elf1Δ* P and the five different S strains (**Figure 3**). We did not commonly observe identical mutations between sequenced biological replicates of each strain, suggesting that either new mutations may arise during the culturing of *elf1Δ* cells before genomic library construction or random errors may be introduced during the library construction and sequencing. Hence, isolating mutations that are consistent across biological replicates is an important aspect in the successful identification of suppressors using whole-genome sequencing.

We identified and confirmed two suppressors in CDS regions in five sequenced S strains. Although mutations in *SPBPJ4664.02* were detected in both S-A1 and S-A2 strains, it is unlikely that *SPBPJ4664.02* is a valid suppressor because S-A1 and S-A2 do not contain a suppressor on the same gene as they are not complementary with each other (data not shown). We also did not confirm *rli1* in S-A3, which did not co-segregate with the S phenotype when backcrossed with *elf1Δ*. Alternatively, we found specific mutations in non-coding regions in S-A1, S-A2 and S-A3. It is possible that these altered non-coding genomic regions alleviate the *elf1Δ* phenotype, which will be addressed in our future studies. Compared to traditional methods such as a linkage assay, which may take years to map a genetic mutation, we identified two suppressors within two months after confirming that a monogenic element caused the S phenotype. With the fast development of whole-genome sequencing technology, we are optimistic that this method will be more efficient to identify consistent genetic mutations in the foreseeable future.

In summary, this protocol provides step-by-step directions to successfully identify suppressor mutations for any gene of interest with a slow-growing defect in liquid culture. The simplicity of this assay allows for the large-scale screening of multiple genetic backgrounds of interest with little hands-on training. There is room to further automate the process by using a liquid handling robot to perform the daily dilutions. Since laboratory manipulation of microorganisms inevitably requires growth in liquid culture, a process that is inherently selective for fitness, we propose that this protocol can be broadly applied to other large-population model organisms such as bacteria and other yeast species.

ACKNOWLEDGEMENTS:

This work was supported by the National Institute of General Medical Sciences, grants 1R15GM119105-01 to K.Z. We thank all reviewers for insightful comments. We also thank James Tucker, Alicia Anderson, Elizabeth Black and Glen Marrs for the discussion and comments on this manuscript.

DISCLOSURES:


The authors declare no endorsements by the manufacturers of the instruments used in this method, and no competing financial interests.


REFERENCES:


1. McKay, J. K., Latta, R. G. Adaptive population divergence: Markers, QTL and traits. *Trends in Ecology and Evolution*. **17** (6), 285-291 (2002).
2. Wood, V., Harris, M. A., et al. PomBase: A comprehensive online resource for fission yeast. *Nucleic Acids Research*. **40** (D1), (2012).
3. de Visser, J. A. G. M., Cooper, T. F., Elena, S. F. The causes of epistasis. *Proceedings of the Royal Society B: Biological Sciences*. **278** (1725), 3617-3624 (2011).
4. Sailer, Z. R., Harms, M. J. Detecting high-order epistasis in nonlinear genotype-phenotype maps. *Genetics*. **205** (3), 107911088 (2017).
5. Kuzmin, E., Costanzo, M., Andrews, B., Boone, C. Synthetic genetic arrays: Automation of yeast genetics. *Cold Spring Harbor Protocols*. **2016** (4), 326-332 (2016).
6. Tong, A. H. Y., Boone, C. Synthetic genetic array analysis in *Saccharomyces cerevisiae*.

- 526 *Methods in Molecular Biology*. **313** (1), 171-192 (2006).
- 527 7. Dixon, S. J., Costanzo, M., Baryshnikova, A., Andrews, B., Boone, C. Systematic Mapping of
528 Genetic Interaction Networks. *Annual Review of Genetics*. **43**, (1), 601-625 (2009).
- 529 8. Boone, C., Bussey, H., Andrews, B. J. Exploring genetic interactions and networks with
530 yeast. *Nature Reviews Genetics*. **8** (6), 437-449 (2007).
- 531 9. Bai, X., Yang, Z., Jiang, H., Lin, S., Zon, L. I. Genetic suppressor screens in haploids. *Methods*
532 *in Cell Biology*. **104**, 129-136 (2011).
- 533 10. Manson, M. D. Allele-specific suppression as a tool to study protein-protein interactions in
534 bacteria. *Methods*. **20** (1), 18-34 (2000).
- 535 11. Motter, A. E., Gulbahce, N., Almaas, E., Barabási, A. L. Predicting synthetic rescues in
536 metabolic networks. *Molecular Systems Biology*. **4**, 168 (2008).
- 537 12. Peterson, R. T., Shaw, S. Y., et al. Chemical suppression of a genetic mutation in a zebrafish
538 model of aortic coarctation. *Nature Biotechnology*. **22** (5), 595-599 (2004).
- 539 13. Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., Muchowski, P. J. A genomic screen in
540 yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington
541 disease. *Nature Genetics*. **37** (5), 526-531 (2005).
- 542 14. Forsburg, S. L., Patton, E., et al. The art and design of genetic screens. *Nature reviews.*
543 *Genetics*. **2** (9), 659-668 (2001).
- 544 15. Johnston, D. S. The art and design of genetic screens. *Genetics*. **3** (March), 176-188 (2002).
- 545 16. Jorgensen, E. M., Mango, S. E. The art and design of genetic screens: *Caenorhabditis*
546 *elegans*. *Nature Reviews Genetics*. **3** (5), 356-369 (2002).
- 547 17. Gocke, E., Müller, L. In vivo studies in the mouse to define a threshold for the genotoxicity
548 of EMS and ENU. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*.
549 **678** (2), 101-107 (2009).
- 550 18. Suzuki, T., Hayashi, M., et al. A comparison of the genotoxicity of ethylnitrosourea and
551 ethyl methanesulfonate in lacZ transgenic mice (Muta(TM)Mouse). *Mutation Research -*
552 *Genetic Toxicology and Environmental Mutagenesis*. **395** (1), 75-82 (1997).
- 553 19. Uttam, J., Alberico, C., De Stasio, E. ENU Mutagenesis. *International C. elegans Meeting*.
554 (1995).
- 555 20. Putrament, A., Baranowska, H., Ejchart, A., Prazmo, W. Manganese Mutagenesis in Yeast.
556 *Methods in Cell Biology*. **20** (C), 25-34 (1978).
- 557 21. Bose, J. L. Chemical and UV mutagenesis. *Methods in Molecular Biology*. **1373**, 111-115
558 (2016).
- 559 22. Ikehata, H., Ono, T. The Mechanisms of UV Mutagenesis. *Journal of Radiation Research*.
560 **52** (2), 115-125 (2011).
- 561 23. Shrivastav, N., Li, D., Essigmann, J. M. Chemical biology of mutagenesis and DNA repair:
562 cellular responses to DNA alkylation. *Carcinogenesis*. **31** (1), 59-70 (2010).
- 563 24. De Stasio, E. A., Dorman, S. Optimization of ENU mutagenesis of *Caenorhabditis elegans*.
564 *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*. **495** (1-2), 81-88
565 (2001).
- 566 25. Probst, F. J., Justice, M. J. Mouse mutagenesis with the chemical supermutagen ENU.
567 *Methods in Enzymology*. **477** (C), 297-312 (2010).
- 568 26. Bähler, J., Wu, J. Q., et al. Heterologous modules for efficient and versatile PCR-based gene
569 targeting in *Schizosaccharomyces pombe*. *Yeast*. **14** (10), 943-951 (1998).


- 570 27. Li, H., Durbin, R. Fast and accurate short read alignment with Burrows – Wheeler
571 transform. *Bioinformatics*. **25** (14), 1754-1760 (2009).
- 572 28. Van der Auwera, G. A., Carneiro, M. O., et al. From fastQ data to high-confidence variant
573 calls: The genome analysis toolkit best practices pipeline. *Current Protocols in*
574 *Bioinformatics*. **43**, 11.10.1-11.10.33 (2013).
- 575 29. Mckenna, A., Hanna, M., et al. The Genome Analysis Toolkit: A MapReduce framework for
576 analyzing next-generation DNA sequencing data. *Genome Research* **20**, 1297-1303 (2010).
- 577 30. Li, H., Handsaker, B., et al. The Sequence Alignment/Map format and SAMtools.
578 *Bioinformatics*. **25** (16), 2078-2079 (2009).
- 579 31. Marayati, B. F., Drayton, A. L., et al. Loss of Elongation-Like Factor 1 Spontaneously Induces
580 Diverse, RNase H-Related Suppressor Mutations in *Schizosaccharomyces pombe*. *Genetics*.
581 **209** (4), 967-981 (2018).
- 582 32. Harris, M. A., Lock, A., Bähler, J., Oliver, S. G., Wood, V. FYPO: The fission yeast phenotype
583 ontology. *Bioinformatics*. **29** (13), 1671-1678 (2013).
- 584 33. Xu, X., Wang, L., Yanagida, M. Whole-Genome Sequencing of Suppressor DNA Mixtures
585 Identifies Pathways That Compensate for Chromosome Segregation Defects in
586 *Schizosaccharomyces pombe*. *G3: Genes/Genomes/Genetics*. **8** (3), 1031-1038 (2018).
- 587 34. Marayati, B. F., Hoskins, V., et al. The fission yeast MTREC and EJC orthologs ensure the
588 maturation of meiotic transcripts during meiosis. *RNA*. **22** (9), 1349-1359 (2016).
- 589
590








A *elf1Δ cue2-1* X *elf1ΔP*



B *elf1Δ rpl2702-1* X *elf1ΔP*



Name of Material/ Equipment	Company	Catalog Number
Adenine, Powder	Acros Organics	147441000
Bacteriology Petri Dish	Corning, Falcon	C351029
D-Glucose Anhydrous, Powder	Fisher Chemical	D16-1
Difco Agar, Granulated	Becton, Dickinson and Co.	214530
DNA extraction buffer		
Focused-ultrasonicator	Covaris Inc.	S220
Gen5 Data Collection and Analysis Software	Biotek, Inc.	GEN5SECURE
Hydrochloric Acid 1N, Liquid	Fisher Chemical	SA48-4
Liquid Rich Media (liquid YEA)		
Microplate Reader, Synergy H1 Hybrid Multi-Mode Reader	Biotek, Inc.	BTH1MG
Rich Media agar plates (YEA plates)		
RNase A/T1 mix	Thermo Fisher Scientific	EN0551
Sterile Polystyrene Inoculating Loop	Corning, Inc.	OS101
Sterile workspace and burners		
Tissue Culture Plate, 96-well Optical Flat Bottom with Low Evaporation Lid	Corning, Falcon	C353072
TruSeq DNA PCR-Free LT/HT Library Prep Kit	Illumina, Inc.	20015962
Yeast Extract, Powder	Fisher Chemical	BP1422-500

Comments/Description

Use at 75 mg/L to make liquid and solid rich media (YEA)

100×15mm, use to grow strains to single colonies on solid rich media

Use at 30 g/L to make liquid and solid rich media (YEA)

Use at 20 g/L to make solid rich media (YEA)

2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-Cl (pH 8.0), 1mM Na₂-EDTA

Alternatively, use QSonica Q800R sonicator/DNA and chromatin shearing system

Or equivalent, must be compatible with the micro-plate reader, use to export data readings from the micro-plate reader

Use to adjust pH to 5.5 in liquid and solid rich media

30 g/L D-Glucose, 5 g/L Yeast Extract, 75 mg/L Adenine, pH adjusted to 5.5 with 1 M HCl

Or equivalent, must read visible light at 600nm wavelength range

30 g/L D-Glucose, 5 g/L Yeast Extract, 75 mg/L Adenine, 20 g/L Agar, pH adjusted to 5.5 with 1 M HCl.

Use according to manufacturer recommendation

Or equivalent, use to transfer colonies from agar plates to 96-well plate

Or equivalent, must have optical flat bottom for micro-plate ready

Use to prepare the whole-genome sequencing library

Use at 5 g/L to make liquid and solid rich media (YEA)



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	A deep-sequencing-assisted, non-chemical-based suppressor screen in the fission yeast <i>Schizosaccharomyces pombe</i>
Author(s):	Bahjat F. Marayati and Ke Zhang

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access ☒ Open Access

Item 2: Please select one of the following items:

- ☒ The Author is **NOT** a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Ke Zhang		
Department:	Biology		
Institution:	Wake Forest University		
Title:	Associate Professor		
Signature:		Date:	9/19/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Editorial comments:

1. Protocol to be filmed should have detailed, step-by-step directions highlighted, which is not necessarily the case; e.g.:

-Section 2: This section is fairly vague (and is perhaps not necessary to film; note that we can show the point that the strains should have a growth defect in another section of the video).

We agree. We don't need to film this section, but we need to be clear that having a growth defect in liquid culture (mutation or drug) is a pre-requirement for the screen.

-Section 6: You have indicated that bioinformatic analysis should be filmed, but not highlighted any of the steps; also the last step highlighted is fairly vague. Please

We won't film the bioinformatics analysis. We will only film the content in Figure 3, and the highlighted portion of step 6.10.

2. 6.6-6.8: It looks like this is geared to the analysis you did for the results (including in the provided scripts); how might it be altered for the protocol as presented, with all sequencing done in triplicate?

Thank you for this important point. We have revised the script in the protocol to better align with the protocol and to analyze triplicates.

3. Results: '...when backcrossing all yfm S with yfm P...' (first paragraph)-the use of the generic 'yfm' seems out of place in this section, which should be focused on specific results. Could this be '...suppressors with parentals' (or similar)? See also later in the paragraph.

We agree that it seems out of place. We have revised the text to "When grown on the same plate for the same amount of time, we confirmed the 2:2 segregation when back-crossing all suppressed strains (S strains) with their parental strains (P strains), which resulted in 2 small (growth defect) and 2 large (suppressor phenotype) colonies. Individual examples for suppressed *elf1Δ*, *clr6-1* and *fal1Δ* cells are shown in Figure 2B. We have confirmed that all isolated S strains carry a monogenic, genetic element that suppresses the slow-growing phenotype of their P strains (data not shown)".

4. Table 1: There should be one sheet per uploaded table; either split into 4 tables or upload as supplemental material. Note also that a 650+ row table will be tricky to include within the final manuscript.

We have split the table into 4 tables and uploaded the tables as supplementary material. We have modified the text to reflect the changes.

Genetics Society of America LICENSE TERMS AND CONDITIONS

Oct 30, 2018

This is a License Agreement between Ke Zhang ("You") and Genetics Society of America ("Genetics Society of America") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Genetics Society of America, and the payment terms and conditions.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	4458851057756
License date	Oct 29, 2018
Licensed content publisher	Genetics Society of America
Licensed content title	Genetics
Licensed content date	Dec 31, 1969
Type of Use	Journal/Magazine
Requestor type	Author of requested content
Format	Electronic
Portion	image/photo
Number of images/photos requested	2
The requesting person/organization is:	Ke Zhang/Wake Forest University
Title or numeric reference of the portion(s)	Figure 4, The confirmation of cue2 and ...mutations as suppressors of elf1, Panel A and C. Figure 8, elf1 P cells demonstrate a ...recovery pattern in liquid culture.
Title of the article or chapter the portion is from	Loss of Elongation-Like Factor 1 Spontaneously Induces Diverse, RNase H-Related Suppressor Mutations in Schizosaccharomyces pombe
Editor of portion(s)	Jac Nickoloff
Author of portion(s)	Ke Zhang
Volume of serial or monograph.	Volume 210
Issue, if republishing an article from a serial	Issue 2
Page range of the portion	974, and 978
Publication date of portion	May 29, 2018
Rights for	Main product and any product related to main product
Duration of use	Current edition and up to 5 years

Creation of copies for the disabled	no
With minor editing privileges	yes
For distribution to	United States
In the following language(s)	Original language of publication
With incidental promotional use	no
The lifetime unit quantity of new product	Up to 499
Title of new article	A deep-sequencing-assisted, spontaneous suppressor screen in the fission yeast <i>Schizosaccharomyces pombe</i>
Lead author	Ke Zhang
Title of targeted journal	JoVE
Publisher	JoVE
Publisher imprint	No
Expected publication date	Jan 2019
Billing Type	Invoice
Billing Address	Ke Zhang Wake Downtown 455 Vine Street Winston Salem, NC 27101 United States Attn: Ke Zhang
Total (may include CCC user fee)	0.00 USD
Terms and Conditions	

TERMS AND CONDITIONS

The following terms are individual to this publisher:

None

Other Terms and Conditions:

STANDARD TERMS AND CONDITIONS

1. Description of Service; Defined Terms. This Reproduction License enables the User to obtain licenses for reproduction of one or more copyrighted works as described in detail on the relevant Order Confirmation (the "Work(s)"). Copyright Clearance Center, Inc. ("CCC") grants licenses through the Service on behalf of the rightsholder identified on the Order Confirmation (the "Rightsholder"). "Reproduction", as used herein, generally means the inclusion of a Work, in whole or in part, in a new work or works, also as described on the Order Confirmation. "User", as used herein, means the person or entity making such reproduction.

2. The terms set forth in the relevant Order Confirmation, and any terms set by the Rightsholder with respect to a particular Work, govern the terms of use of Works in connection with the Service. By using the Service, the person transacting for a reproduction license on behalf of the User represents and warrants that he/she/it (a) has been duly authorized by the User to accept, and hereby does accept, all such terms and conditions on

behalf of User, and (b) shall inform User of all such terms and conditions. In the event such person is a “freelancer” or other third party independent of User and CCC, such party shall be deemed jointly a “User” for purposes of these terms and conditions. In any event, User shall be deemed to have accepted and agreed to all such terms and conditions if User republishes the Work in any fashion.

3. Scope of License; Limitations and Obligations.

3.1 All Works and all rights therein, including copyright rights, remain the sole and exclusive property of the Rightsholder. The license created by the exchange of an Order Confirmation (and/or any invoice) and payment by User of the full amount set forth on that document includes only those rights expressly set forth in the Order Confirmation and in these terms and conditions, and conveys no other rights in the Work(s) to User. All rights not expressly granted are hereby reserved.

3.2 General Payment Terms: You may pay by credit card or through an account with us payable at the end of the month. If you and we agree that you may establish a standing account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are payable upon their delivery to you (or upon our notice to you that they are available to you for downloading). After 30 days, outstanding amounts will be subject to a service charge of 1-1/2% per month or, if less, the maximum rate allowed by applicable law. Unless otherwise specifically set forth in the Order Confirmation or in a separate written agreement signed by CCC, invoices are due and payable on “net 30” terms. While User may exercise the rights licensed immediately upon issuance of the Order Confirmation, the license is automatically revoked and is null and void, as if it had never been issued, if complete payment for the license is not received on a timely basis either from User directly or through a payment agent, such as a credit card company.

3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is “one-time” (including the editions and product family specified in the license), (ii) is non-exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions (such as, but not limited to, limitations on duration of use or circulation) included in the Order Confirmation or invoice and/or in these terms and conditions. Upon completion of the licensed use, User shall either secure a new permission for further use of the Work(s) or immediately cease any new use of the Work(s) and shall render inaccessible (such as by deleting or by removing or severing links or other locators) any further copies of the Work (except for copies printed on paper in accordance with this license and still in User's stock at the end of such period).

3.4 In the event that the material for which a republication license is sought includes third party materials (such as photographs, illustrations, graphs, inserts and similar materials) which are identified in such material as having been used by permission, User is responsible for identifying, and seeking separate licenses (under this Service or otherwise) for, any of such third party materials; without a separate license, such third party materials may not be used.

3.5 Use of proper copyright notice for a Work is required as a condition of any license granted under the Service. Unless otherwise provided in the Order Confirmation, a proper copyright notice will read substantially as follows: “Republished with permission of [Rightsholder’s name], from [Work's title, author, volume, edition number and year of copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice

must be provided in a reasonably legible font size and must be placed either immediately adjacent to the Work as used (for example, as part of a by-line or footnote but not as a separate electronic link) or in the place where substantially all other credits or notices for the new work containing the republished Work are located. Failure to include the required notice results in loss to the Rightsholder and CCC, and the User shall be liable to pay liquidated damages for each such failure equal to twice the use fee specified in the Order Confirmation, in addition to the use fee itself and any other fees and charges specified.

3.6 User may only make alterations to the Work if and as expressly set forth in the Order Confirmation. No Work may be used in any way that is defamatory, violates the rights of third parties (including such third parties' rights of copyright, privacy, publicity, or other tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In addition, User may not conjoin a Work with any other material that may result in damage to the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any infringement of any rights in a Work and to cooperate with any reasonable request of CCC or the Rightsholder in connection therewith.

4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and their respective employees and directors, against all claims, liability, damages, costs and expenses, including legal fees and expenses, arising out of any use of a Work beyond the scope of the rights granted herein, or any use of a Work which has been altered in any unauthorized way by User, including claims of defamation or infringement of rights of copyright, publicity, privacy or other tangible or intangible property.

5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES FOR LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK, EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their respective employees and directors) shall not exceed the total amount actually paid by User for this license. User assumes full liability for the actions and omissions of its principals, employees, agents, affiliates, successors and assigns.

6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED "AS IS". CCC HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS, GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.

7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User of a Work beyond the scope of the license set forth in the Order Confirmation and/or these terms and conditions, shall be a material breach of the license created by the Order Confirmation and these terms and conditions. Any breach not cured within 30 days of

written notice thereof shall result in immediate termination of such license without further notice. Any unauthorized (but licensable) use of a Work that is terminated immediately upon notice thereof may be liquidated by payment of the Rightsholder's ordinary license price therefor; any unauthorized (and unlicensable) use that is not terminated immediately for any reason (including, for example, because materials containing the Work cannot reasonably be recalled) will be subject to all remedies available at law or in equity, but in no event to a payment of less than three times the Rightsholder's ordinary license price for the most closely analogous licensable use plus Rightsholder's and/or CCC's costs and expenses incurred in collecting such payment.

8. Miscellaneous.

8.1 User acknowledges that CCC may, from time to time, make changes or additions to the Service or to these terms and conditions, and CCC reserves the right to send notice to the User by electronic mail or otherwise for the purposes of notifying User of such changes or additions; provided that any such changes or additions shall not apply to permissions already secured and paid for.

8.2 Use of User-related information collected through the Service is governed by CCC's privacy policy, available online

here: <http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html>.

8.3 The licensing transaction described in the Order Confirmation is personal to User. Therefore, User may not assign or transfer to any other person (whether a natural person or an organization of any kind) the license created by the Order Confirmation and these terms and conditions or any rights granted hereunder; provided, however, that User may assign such license in its entirety on written notice to CCC in the event of a transfer of all or substantially all of User's rights in the new material which includes the Work(s) licensed under this Service.

8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed by the parties. The Rightsholder and CCC hereby object to any terms contained in any writing prepared by the User or its principals, employees, agents or affiliates and purporting to govern or otherwise relate to the licensing transaction described in the Order Confirmation, which terms are in any way inconsistent with any terms set forth in the Order Confirmation and/or in these terms and conditions or CCC's standard operating procedures, whether such writing is prepared prior to, simultaneously with or subsequent to the Order Confirmation, and whether such writing appears on a copy of the Order Confirmation or in a separate instrument.

8.5 The licensing transaction described in the Order Confirmation document shall be governed by and construed under the law of the State of New York, USA, without regard to the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding arising out of, in connection with, or related to such licensing transaction shall be brought, at CCC's sole discretion, in any federal or state court located in the County of New York, State of New York, USA, or in any federal or state court whose geographical jurisdiction covers the location of the Rightsholder set forth in the Order Confirmation. The parties expressly submit to the personal jurisdiction and venue of each such federal or state court. If you have any comments or questions about the Service or Copyright Clearance Center, please contact us at 978-750-8400 or send an e-mail to info@copyright.com.

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.



Chromosome	Position	Gene ID	Coding/Exon ID	Original Sequence
I	3477396	transcript:SPAC328.02.1	-	CA
I	3160042	transcript:SPAC3G9.11c.1	-	C
I	3160041	transcript:SPAC3G9.11c.1	-	G
I	3160038	transcript:SPAC3G9.11c.1	-	C
I	3160037	transcript:SPAC3G9.11c.1	-	A
I	3160036	transcript:SPAC3G9.11c.1	-	G
I	3160028	transcript:SPAC3G9.11c.1	-	G
II	1952886	-	gene:SPN0	A
II	693499	transcript:SPBPJ4664.02.1	CDS:SPB0	AGC
II	692303	transcript:SPBPJ4664.02.1	CDS:SPB0	CTG
II	692301	transcript:SPBPJ4664.02.1	CDS:SPB0	GTT
II	670967	transcript:SPBC947.04.1	CDS:SPB0	TAT
II	413474	transcript:SPBC106.18.1	-	C
II	413473	transcript:SPBC106.18.1	-	A
I	4926046	transcript:SPAC1B3.01c.1	-	C
I	4926046	transcript:SPAPB8E5.09.1	-	C
I	4514505	transcript:SPAC27D7.03c.1	-	C
I	4514503	transcript:SPAC27D7.03c.1	-	AGC
I	4361998	-	gene:SPN0	C
I	4361998	-	gene:SPN0	C
I	3879455	-	gene:SPN0	C
I	3879455	transcript:SPAC1071.13.1	-	C
II	3856896	-	gene:SPN0	A
II	3799387	transcript:SPBC21C3.02c.1	-	G
II	3799385	transcript:SPBC21C3.02c.1	-	T
II	3799350	transcript:SPBC21C3.02c.1	-	G
I	3645128	transcript:SPAC8C9.03.1	-	A
I	3645110	transcript:SPAC8C9.03.1	-	A
II	3410436	-	gene:SPN0	G
II	3380128	-	gene:SPN0	CT
II	2591913	transcript:SPBC2G5.07c.1	-	T
I	2525188	-	gene:SPN0	A
I	2525182	-	gene:SPN0	G
I	2231756	transcript:SPAC18G6.09c.1	-	T
II	2197587	transcript:SPBC17G9.13c.1	-	C
II	2132608	transcript:SPBC1711.01c.1	CDS:SPB0	AAA
II	2132607	transcript:SPBC1711.01c.1	CDS:SPB0	AAA
II	2132603	transcript:SPBC1711.01c.1	CDS:SPB0	AAG
II	2132602	transcript:SPBC1711.01c.1	CDS:SPB0	AAG
III	2069621	transcript:SPCPB1C11.01.1	-	G
I	1954162	-	gene:SPN0	C

I	1954162 -	gene:SPN(C
II	1952889 -	gene:SPN(C
II	1818127 transcript:SPBC9B6.03.1	- A
III	1712983 transcript:SPCC191.05c.1	- G
III	1712983 transcript:SPCC191.06.1	- G
III	1529709 transcript:SPCC584.01c.1	- AGTATGCTTTTATT
III	1529707 transcript:SPCC584.01c.1	- C
III	1529703 transcript:SPCC584.01c.1	- G
I	1494938 transcript:SPAC5D6.10c.1	CDS:SPA(C
I	1494938 transcript:SPAC5D6.12.1	- C
II	1389165 transcript:SPBC8D2.16c.1	- A
II	1389161 transcript:SPBC8D2.16c.1	- C
I	1358820 -	gene:SPN(G
I	1358820 -	gene:SPN(G
II	1264820 -	gene:SPN(A
II	1264817 -	gene:SPN(G
II	1264816 -	gene:SPN(G
II	890630 -	gene:SPN(A
II	890630 transcript:SPBC713.14c.1	- A
III	822725 transcript:SPCC1393.11.1	- C
II	716295 transcript:SPBC119.02.1	- G
II	694720 transcript:SPBPJ4664.02.1	CDS:SPB(AAC
II	693529 transcript:SPBPJ4664.02.1	CDS:SPB(CTT
II	693527 transcript:SPBPJ4664.02.1	CDS:SPB(CTT
II	693522 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	693520 transcript:SPBPJ4664.02.1	CDS:SPB(TCT
II	693508 transcript:SPBPJ4664.02.1	CDS:SPB(CCA
II	693493 transcript:SPBPJ4664.02.1	CDS:SPB(CTG
II	465486 transcript:SPBC428.11.1	- C
I	453369 transcript:SPAC23E2.03c.1	- G
III	431932 transcript:SPCC306.11.1	- A
III	208138 transcript:SPCC1235.17.1	- C
I	5426636 -	gene:SPN(C
I	5321699 -	gene:SPN(C
I	5123565 transcript:SPAC29A4.11.1	- T
I	5123442 transcript:SPAC29A4.11.1	- T
I	5123329 -	gene:SPN(G
I	5123329 transcript:SPAC29A4.11.1	- G
I	4235582 transcript:SPAC1F7.08.1	- G
I	4235580 transcript:SPAC1F7.08.1	- C
II	4209406 transcript:SPBC342.04.1	- C
I	4177986 transcript:SPAC25B8.12c.1	- T
I	4177982 transcript:SPAC25B8.12c.1	- C
I	4177980 transcript:SPAC25B8.12c.1	- G

I	4177974 transcript:SPAC25B8.12c.1	-	G
I	3995046 transcript:SPAPB15E9.06.1	-	C
I	3992188 -	gene:SPN	G
I	3992188 transcript:SPAPB15E9.02c.1	CDS:SPA	G
II	3980468 -	gene:SPN	C
II	3799350 transcript:SPBC21C3.02c.1	-	G
II	3512948 -	gene:SPN	A
II	3380151 -	gene:SPN	A
I	3300826 -	gene:SPN	G
I	3033347 -	gene:SPN	C
II	2579452 transcript:SPBC2G5.02c.1	-	T
II	2528014 -	gene:SPN	C
II	2528014 -	gene:SPN	C
I	2231735 transcript:SPAC18G6.09c.1	-	C
III	2074540 transcript:SPCPB1C11.02.1	-	C
II	1952856 -	gene:SPN	C
II	1952848 -	gene:SPN	C
I	1845954 transcript:SPAC1399.02.1	-	C
I	1845950 transcript:SPAC1399.02.1	-	G
II	1812797 transcript:SPBC9B6.02c.1	CDS:SPB	GAC
III	1759072 transcript:SPCC1450.14c.1	-	T
III	1712983 transcript:SPCC191.05c.1	-	G
III	1712983 transcript:SPCC191.06.1	-	G
II	1389139 transcript:SPBC8D2.16c.1	-	C
II	1312254 -	gene:SPN	C
II	1312250 -	gene:SPN	C
I	1290605 -	gene:SPN	A
III	970548 -	gene:SPN	C
II	645094 transcript:SPBC947.13.1	-	G
I	453369 transcript:SPAC23E2.03c.1	-	G
III	431926 transcript:SPCC306.11.1	-	G
III	207507 transcript:SPCC1235.17.1	-	C
III	207495 transcript:SPCC1235.17.1	-	C
II	153579 transcript:SPBC1683.06c.1	-	C
II	153579 transcript:SPBC1683.07.1	CDS:SPB	AGC
II	153578 transcript:SPBC1683.06c.1	-	G
II	153578 transcript:SPBC1683.07.1	CDS:SPB	AGC
II	153557 transcript:SPBC1683.06c.1	-	G
II	153557 transcript:SPBC1683.07.1	-	G
II	153554 transcript:SPBC1683.06c.1	-	C
II	153554 transcript:SPBC1683.07.1	-	C
II	153551 transcript:SPBC1683.06c.1	-	ACG
II	153551 transcript:SPBC1683.07.1	-	ACG
II	153549 transcript:SPBC1683.06c.1	-	A

II	153549	transcript:SPBC1683.07.1	-	A
II	153548	transcript:SPBC1683.06c.1	-	G
II	153548	transcript:SPBC1683.07.1	-	G
II	153543	transcript:SPBC1683.06c.1	-	A
II	153543	transcript:SPBC1683.07.1	-	A
II	153540	transcript:SPBC1683.06c.1	-	G
II	153540	transcript:SPBC1683.07.1	-	G
II	153538	transcript:SPBC1683.06c.1	-	G
II	153538	transcript:SPBC1683.07.1	-	G
II	153535	transcript:SPBC1683.06c.1	-	G
II	153535	transcript:SPBC1683.07.1	-	G
II	153532	transcript:SPBC1683.06c.1	-	C
II	153532	transcript:SPBC1683.07.1	-	C
I	3993810	transcript:SPAPB15E9.02c.1	-	T
I	3993810	transcript:SPAPB15E9.06.1	-	T
I	3160028	transcript:SPAC3G9.11c.1	-	G
II	692303	transcript:SPBPJ4664.02.1	CDS:SPB CTG	
II	692301	transcript:SPBPJ4664.02.1	CDS:SPB GTT	
II	670961	transcript:SPBC947.04.1	CDS:SPB GCA	
I	5321699	-	gene:SPN C	
I	4675972	transcript:SPAC144.12.1	-	C
I	4675971	transcript:SPAC144.12.1	-	A
I	4514503	transcript:SPAC27D7.03c.1	-	AG
I	4235582	transcript:SPAC1F7.08.1	-	G
I	3993829	transcript:SPAPB15E9.02c.1	-	G
I	3993829	transcript:SPAPB15E9.06.1	-	G
II	3862860	transcript:SPBC23E6.09.1	-	C
II	3862856	transcript:SPBC23E6.09.1	-	G
II	3862847	transcript:SPBC23E6.09.1	-	C
II	3512948	-	gene:SPN A	
II	3512925	-	gene:SPN C	
I	3477396	transcript:SPAC328.02.1	-	CA
II	3161493	transcript:SPBC609.01.1	-	A
I	3160042	transcript:SPAC3G9.11c.1	-	C
I	3160041	transcript:SPAC3G9.11c.1	-	G
I	3160038	transcript:SPAC3G9.11c.1	-	C
I	3160037	transcript:SPAC3G9.11c.1	-	A
I	3160036	transcript:SPAC3G9.11c.1	-	G
I	3033347	-	gene:SPN C	
I	2520643	-	gene:SPN A	
I	2520643	-	gene:SPN A	
III	2309611	-	gene:SPN TA	
III	1925650	transcript:SPCC74.02c.1	-	C
III	1925626	transcript:SPCC74.02c.1	-	C

II	1750215 -	gene:SPN(TCA
II	1750208 -	gene:SPN(A
II	1750198 -	gene:SPN(C
II	1750196 -	gene:SPN(C
I	1509738 transcript:SPAC5D6.02c.1	- G
II	1389165 transcript:SPBC8D2.16c.1	- A
II	1389161 transcript:SPBC8D2.16c.1	- C
I	1149948 transcript:SPAC56F8.13.1	CDS:SPA(ACA
I	1149948 transcript:SPAC56F8.14c.1	- C
III	970548 -	gene:SPN(C
II	561064 -	gene:SPN(T
II	521747 -	gene:SPN(A
II	520627 -	gene:SPN(C
III	415596 transcript:SPCC306.04c.1	- T
III	237048 transcript:SPCC1529.01.1	- G
I	216147 transcript:SPAC24B11.09.1	- C
II	113239 transcript:SPBC359.03c.1	- G
I	5123329 -	gene:SPN(G
I	5123329 transcript:SPAC29A4.11.1	- G
I	4235601 transcript:SPAC1F7.08.1	- A
I	4235598 transcript:SPAC1F7.08.1	- A
I	3995045 transcript:SPAPB15E9.06.1	- G
II	3980468 -	gene:SPN(C
I	3580034 -	gene:SPN(C
I	3580034 transcript:SPAC17A2.12.1	- C
II	3512961 -	gene:SPN(TCAGTAAAAACTA
I	3160024 transcript:SPAC3G9.11c.1	- A
II	3050446 transcript:SPBC13E7.05.1	CDS:SPB(TAT
II	2579484 transcript:SPBC2G5.02c.1	- C
I	2401096 -	- C
I	2231762 transcript:SPAC18G6.09c.1	- T
II	2203175 transcript:SPBC14C8.01c.1	- T
II	2197587 transcript:SPBC17G9.13c.1	- C
III	2167597 transcript:SPCC1620.11.1	CDS:SPC(TTC
III	2167597 transcript:SPCC1620.12c.1	- T
III	2167592 transcript:SPCC1620.11.1	CDS:SPC(CAAA
III	2167592 transcript:SPCC1620.12c.1	- CAAA
III	2167590 transcript:SPCC1620.11.1	CDS:SPC(C
III	2167590 transcript:SPCC1620.12c.1	- C
III	2167588 transcript:SPCC1620.11.1	CDS:SPC(CTT
III	2167588 transcript:SPCC1620.12c.1	- T
II	2132608 transcript:SPBC1711.01c.1	CDS:SPB(AAA
II	2132607 transcript:SPBC1711.01c.1	CDS:SPB(AAA
II	2132603 transcript:SPBC1711.01c.1	CDS:SPB(AAG

II	2132602	transcript:SPBC1711.01c.1	CDS:SPB0AAG
III	2074540	transcript:SPCPB1C11.02.1	- C
I	1955853	-	gene:SPN0T
I	1955853	-	gene:SPN0T
III	961176	transcript:SPCC1742.01.1	CDS:SPC0ACA
II	890288	-	gene:SPN0GAAA
II	890288	transcript:SPBC713.13.1	CDS:SPB0GAAA
II	890288	transcript:SPBC713.14c.1	CDS:SPB0GAAA
II	693499	transcript:SPBPJ4664.02.1	CDS:SPB0AGC
II	692442	transcript:SPBPJ4664.02.1	CDS:SPB0AGT
II	670963	transcript:SPBC947.04.1	CDS:SPB0GCA
I	453369	transcript:SPAC23E2.03c.1	- G
III	208132	transcript:SPCC1235.17.1	- G
III	46959	transcript:SPCC1884.02.1	- A
III	46959	transcript:SPCC757.02c.1	- A
II	4165206	transcript:SPBC14F5.06.1	CDS:SPB0G
I	3477396	transcript:SPAC328.02.1	- CA
I	3160042	transcript:SPAC3G9.11c.1	- C
I	3160041	transcript:SPAC3G9.11c.1	- G
I	3160038	transcript:SPAC3G9.11c.1	- C
I	3160037	transcript:SPAC3G9.11c.1	- A
I	3160036	transcript:SPAC3G9.11c.1	- G
I	3160028	transcript:SPAC3G9.11c.1	- G
III	1529703	transcript:SPCC584.01c.1	- G
II	1389165	transcript:SPBC8D2.16c.1	- A
II	465486	transcript:SPBC428.11.1	- C
I	5426666	-	gene:SPN0G
I	5426664	-	gene:SPN0A
I	5271466	-	gene:SPN0A
I	5271432	-	gene:SPN0C
I	5173430	-	gene:SPN0G
I	4926094	transcript:SPAC1B3.01c.1	- TAAA
I	4926093	transcript:SPAC1B3.01c.1	- A
I	4926081	transcript:SPAC1B3.01c.1	- TGAATGC
I	4926078	transcript:SPAC1B3.01c.1	- A
I	3995046	transcript:SPAPB15E9.06.1	- C
II	3980468	-	gene:SPN0C
II	3856940	-	gene:SPN0A
II	3856937	-	gene:SPN0C
II	3856935	-	gene:SPN0C
II	3856934	-	gene:SPN0A
II	3856931	-	gene:SPN0G
II	3856928	-	gene:SPN0A
II	3856922	-	gene:SPN0TGGAAGA

II	3799350 transcript:SPBC21C3.02c.1	-	G
I	3645103 transcript:SPAC8C9.03.1	-	C
I	3580034 -	gene:SPN	C
I	3580034 transcript:SPAC17A2.12.1	-	C
I	3576929 transcript:SPAC17A2.11.1	-	C
II	3512948 -	gene:SPN	A
II	3380128 -	gene:SPN	C
II	3329998 -	gene:SPN	G
I	3301568 -	gene:SPN	G
I	3301565 -	gene:SPN	C
II	3161493 transcript:SPBC609.01.1	-	A
I	3160024 transcript:SPAC3G9.11c.1	-	A
II	3050441 transcript:SPBC13E7.05.1	CDS:SPB	AAT
II	2591933 transcript:SPBC2G5.07c.1	-	G
II	2591911 transcript:SPBC2G5.07c.1	-	G
II	2579477 transcript:SPBC2G5.02c.1	-	G
II	2132606 transcript:SPBC1711.01c.1	CDS:SPB	AAA
II	2132604 transcript:SPBC1711.01c.1	CDS:SPB	T
II	2132601 transcript:SPBC1711.01c.1	CDS:SPB	C
III	2069621 transcript:SPCPB1C11.01.1	-	G
II	1964110 -	gene:SPN	C
III	1712983 transcript:SPCC191.05c.1	-	G
III	1712983 transcript:SPCC191.06.1	-	G
III	1674639 -	gene:SPN	A
II	1389161 transcript:SPBC8D2.16c.1	-	C
III	1302685 transcript:SPCC1322.08.1	-	C
III	1302674 transcript:SPCC1322.08.1	-	C
I	1148170 transcript:SPAC56F8.14c.1	-	A
I	1148167 transcript:SPAC56F8.14c.1	-	A
II	1104979 -	gene:SPN	G
II	1104979 transcript:SPBC1709.04c.1	-	G
II	1045366 transcript:SPBC337.08c.1	CDS:SPB	CTT
II	1045363 transcript:SPBC337.08c.1	CDS:SPB	CAC
II	1019534 transcript:SPBC146.10.1	-	T
III	961170 transcript:SPCC1742.01.1	CDS:SPC	GGT
III	958265 -	gene:SPN	A
III	958265 -	gene:SPN	A
III	958265 -	gene:SPN	A
III	958262 -	gene:SPN	TGAA
III	958262 -	gene:SPN	TGAA
III	958262 -	gene:SPN	TGAA
III	827274 transcript:SPCC1393.13.1	-	T
III	822725 transcript:SPCC1393.11.1	-	C
II	695689 transcript:SPBPJ4664.02.1	CDS:SPB	CTG

II	695630 transcript:SPBPJ4664.02.1	CDS:SPB CCAATTACTAGTTC
II	693522 transcript:SPBPJ4664.02.1	CDS:SPB AGT
II	693520 transcript:SPBPJ4664.02.1	CDS:SPB TCT
II	693508 transcript:SPBPJ4664.02.1	CDS:SPB CCA
II	693499 transcript:SPBPJ4664.02.1	CDS:SPB AGC
II	693493 transcript:SPBPJ4664.02.1	CDS:SPB CTG
II	670973 transcript:SPBC947.04.1	CDS:SPB ACT
II	670965 transcript:SPBC947.04.1	CDS:SPB CCC
III	568658 -	gene:SPN C
III	568658 transcript:SPCC1672.04c.1	- C
II	520668 -	gene:SPN G
II	520666 -	gene:SPN A
II	520664 -	gene:SPN TGA
II	520661 -	gene:SPN G
II	520659 -	gene:SPN G
III	467918 transcript:SPCC4G3.03.1	- C
I	453369 transcript:SPAC23E2.03c.1	- G
III	237048 transcript:SPCC1529.01.1	- G
III	69566 transcript:SPCC757.11c.1	- T
III	69562 transcript:SPCC757.11c.1	- C
III	69559 transcript:SPCC757.11c.1	- C
III	69555 transcript:SPCC757.11c.1	- T
I	5321726 -	gene:SPN A
I	5321721 -	gene:SPN A
I	4911430 -	gene:SPN A
II	4209406 transcript:SPBC342.04.1	- C
I	3993810 transcript:SPAPB15E9.02c.1	- T
I	3993810 transcript:SPAPB15E9.06.1	- T
I	3992214 -	gene:SPN C
I	3992214 transcript:SPAPB15E9.02c.1	CDS:SPA C
I	3992188 -	gene:SPN G
I	3992188 transcript:SPAPB15E9.02c.1	CDS:SPA G
II	3980468 -	gene:SPN C
I	3645141 transcript:SPAC8C9.03.1	- G
I	3645139 transcript:SPAC8C9.03.1	- C
I	3645128 transcript:SPAC8C9.03.1	- A
I	3610418 -	gene:SPN G
I	3610418 -	gene:SPN G
I	3610418 transcript:SPAC17G6.11c.1	- G
I	3610417 -	gene:SPN A
I	3610417 -	gene:SPN A
I	3610417 transcript:SPAC17G6.11c.1	- A
I	3580064 -	gene:SPN TACAATTAA
I	3580064 transcript:SPAC17A2.12.1	- TACAATTAA

I	3580061 -	gene:SPN(A
I	3580061 transcript:SPAC17A2.12.1	- A
II	3380128 -	gene:SPN(C
I	3301538 -	gene:SPN(C
I	3300820 -	gene:SPN(G
I	3166796 -	- T
I	3166796 -	gene:SPN(T
I	3160021 transcript:SPAC3G9.11c.1	- C
I	3033347 -	gene:SPN(C
I	2416364 transcript:SPAC6B12.04c.1	- A
I	2416364 transcript:SPAC6B12.18.1	- A
I	2231762 transcript:SPAC18G6.09c.1	- T
II	2204920 -	gene:SPN(G
II	2203175 transcript:SPBC14C8.01c.1	- T
III	2074540 transcript:SPCPB1C11.02.1	- C
II	1952889 -	gene:SPN(C
II	1952886 -	gene:SPN(A
III	1712983 transcript:SPCC191.05c.1	- G
III	1712983 transcript:SPCC191.06.1	- G
I	1665245 transcript:SPAC343.21.1	- G
I	1665240 transcript:SPAC343.21.1	- T
II	1554361 -	gene:SPN(C
II	1389160 transcript:SPBC8D2.16c.1	- TC
I	1359503 -	gene:SPN(T
II	1104985 -	gene:SPN(C
II	1104985 transcript:SPBC1709.04c.1	- C
II	1104984 -	gene:SPN(A
II	1104984 transcript:SPBC1709.04c.1	- A
II	1104981 -	gene:SPN(AAC
II	1104981 transcript:SPBC1709.04c.1	- AAC
III	961171 transcript:SPCC1742.01.1	CDS:SPC(ACT
II	890282 -	gene:SPN(T
II	890282 transcript:SPBC713.13.1	CDS:SPB(ACC
II	890282 transcript:SPBC713.14c.1	CDS:SPB(TAC
II	890279 -	gene:SPN(G
II	890279 transcript:SPBC713.13.1	CDS:SPB(CTA
II	890279 transcript:SPBC713.14c.1	CDS:SPB(CCT
II	890277 -	gene:SPN(T
II	890277 transcript:SPBC713.13.1	CDS:SPB(CTA
II	890277 transcript:SPBC713.14c.1	CDS:SPB(ATT
II	890273 -	gene:SPN(G
II	890273 transcript:SPBC713.13.1	CDS:SPB(CTT
II	890273 transcript:SPBC713.14c.1	CDS:SPB(TCT
II	693574 transcript:SPBPJ4664.02.1	CDS:SPB(TACACCAATTACT/

II	692442 transcript:SPBPJ4664.02.1	CDS:SPB AGT
I	414099 transcript:SPAC31A2.12.1	- C
I	414098 transcript:SPAC31A2.12.1	- C
II	3883700 transcript:SPBC211.05.1	- A
II	3883700 transcript:SPBC211.06.1	- A
I	2327021 -	gene:SPN C
I	2327021 transcript:SPAC6C3.03c.1	- C
I	1905516 transcript:SPAC110.05.1	- C
III	1302685 transcript:SPCC1322.08.1	- C
II	1045183 transcript:SPBC337.08c.1	CDS:SPB GAT
III	180262 transcript:SPCC1235.03.1	CDS:SPC CCGATCTCTTGCTA
I	5322103 transcript:SPAP8A3.05.1	- A
I	5078848 transcript:SPAC1006.05c.1	- G
I	4235601 transcript:SPAC1F7.08.1	- A
II	3856940 -	gene:SPN A
II	3856937 -	gene:SPN C
II	3856935 -	gene:SPN C
II	3856934 -	gene:SPN A
II	3856931 -	gene:SPN G
II	3856930 -	gene:SPN G
II	3856923 -	gene:SPN GGAAGA
II	3856896 -	gene:SPN A
I	3580034 -	gene:SPN C
I	3580034 transcript:SPAC17A2.12.1	- C
I	3578659 -	gene:SPN G
I	3578659 transcript:SPAC17A2.11.1	- G
II	3513908 -	gene:SPN A
II	3513908 -	gene:SPN A
II	3513904 -	gene:SPN A
II	3513904 -	gene:SPN A
II	3513900 -	gene:SPN A
II	3513900 -	gene:SPN A
II	3512948 -	gene:SPN A
II	3512947 -	gene:SPN A
II	3498954 transcript:SPBPB7E8.02.1	- A
I	3477403 transcript:SPAC328.02.1	- A
II	3410437 -	gene:SPN G
II	3380128 -	gene:SPN C
II	3161493 transcript:SPBC609.01.1	- A
I	2932642 -	gene:SPN C
I	2932642 transcript:SPAC2E1P3.04.1	- C
II	2826100 transcript:SPBC19C7.04c.1	- G
I	2401096 -	- C
I	2231735 transcript:SPAC18G6.09c.1	- C

II	2197587 transcript:SPBC17G9.13c.1	- C
II	2132612 transcript:SPBC1711.01c.1	CDS:SPB CCGT
II	2132601 transcript:SPBC1711.01c.1	CDS:SPB CTTTTTTTTTA
III	2113232 -	gene:SPN G
III	2074510 transcript:SPCPB1C11.02.1	- C
II	1952900 -	gene:SPN G
II	1952897 -	gene:SPN C
II	1941589 -	gene:SPN G
III	1925626 transcript:SPCC74.02c.1	- C
II	1750208 -	gene:SPN A
II	1554383 -	gene:SPN G
I	1359552 -	gene:SPN T
I	1359548 -	gene:SPN T
III	1302674 transcript:SPCC1322.08.1	- C
III	1239230 transcript:SPCC645.06c.1	- G
I	1152925 transcript:SPAC56F8.15.1	- C
II	1104941 -	gene:SPN G
II	1104941 -	gene:SPN G
II	1104941 transcript:SPBC1709.04c.1	- G
III	961170 transcript:SPCC1742.01.1	CDS:SPC GGT
II	716295 transcript:SPBC119.02.1	- G
II	694720 transcript:SPBPJ4664.02.1	CDS:SPB AAC
II	693574 transcript:SPBPJ4664.02.1	CDS:SPB TACACCAATTACT/
III	568680 -	gene:SPN TTA
III	568680 transcript:SPCC1672.04c.1	- TTA
II	561064 -	gene:SPN T
I	232681 transcript:SPAC24B11.13.1	- A
III	231447 -	gene:SPN C
III	208136 transcript:SPCC1235.17.1	- T
II	153578 transcript:SPBC1683.06c.1	- G
II	153578 transcript:SPBC1683.07.1	CDS:SPB AGC
I	5173430 -	gene:SPN G
I	5123329 -	gene:SPN G
I	5123329 transcript:SPAC29A4.11.1	- G
I	5078848 transcript:SPAC1006.05c.1	- G
I	3993810 transcript:SPAPB15E9.02c.1	- T
I	3993810 transcript:SPAPB15E9.06.1	- T
II	3799433 transcript:SPBC21C3.02c.1	- C
I	3610433 -	gene:SPN G
I	3610433 -	gene:SPN G
I	3610433 transcript:SPAC17G6.11c.1	- G
I	3610425 -	gene:SPN G
I	3610425 -	gene:SPN G
I	3610425 transcript:SPAC17G6.11c.1	- G

I	3610417 -	gene:SPN(A
I	3610417 -	gene:SPN(A
I	3610417 transcript:SPAC17G6.11c.1	- A
I	3576439 -	gene:SPN(G
II	3540075 transcript:SPBC1105.17.1	- A
II	3512948 -	gene:SPN(A
II	3380176 -	gene:SPN(G
II	3380174 -	gene:SPN(TCG
II	3380169 -	gene:SPN(TAAC
II	3380164 -	gene:SPN(TCCA
II	3380151 -	gene:SPN(A
II	3161493 transcript:SPBC609.01.1	- A
I	3033347 -	gene:SPN(C
II	2579458 transcript:SPBC2G5.02c.1	- C
I	2525182 -	gene:SPN(G
I	2231762 transcript:SPAC18G6.09c.1	- T
I	2231735 transcript:SPAC18G6.09c.1	- C
II	2203098 transcript:SPBC14C8.01c.1	- G
II	2203097 transcript:SPBC14C8.01c.1	- G
II	2203092 transcript:SPBC14C8.01c.1	- G
II	2203090 transcript:SPBC14C8.01c.1	- T
II	2203088 transcript:SPBC14C8.01c.1	- T
II	2203086 transcript:SPBC14C8.01c.1	- C
III	2069621 transcript:SPCPB1C11.01.1	- G
II	1955514 -	gene:SPN(G
II	1818108 transcript:SPBC9B6.03.1	- C
II	1750216 -	gene:SPN(C
II	1678218 transcript:SPBC19C2.04c.1	- AT
I	1494950 transcript:SPAC5D6.10c.1	CDS:SPA AGA
I	1494950 transcript:SPAC5D6.12.1	- G
I	1494938 transcript:SPAC5D6.10c.1	CDS:SPA C
I	1494938 transcript:SPAC5D6.12.1	- C
III	1302674 transcript:SPCC1322.08.1	- C
II	1171363 transcript:SPBC409.19c.1	- T
II	1171362 transcript:SPBC409.19c.1	- T
II	1078283 transcript:SPBC1734.09.1	- G
II	837481 transcript:SPBC36.02c.1	- G
II	837476 transcript:SPBC36.02c.1	- G
II	837475 transcript:SPBC36.02c.1	- T
III	761531 transcript:SPCC1020.10.1	- C
II	693100 transcript:SPBPJ4664.02.1	CDS:SPB CAGTTCTACACCA
II	670978 transcript:SPBC947.04.1	CDS:SPB ACT
II	670968 transcript:SPBC947.04.1	CDS:SPB TAT
II	561064 -	gene:SPN(T

II	521748 -	gene:SPN(A
III	431910 transcript:SPCC306.11.1	- C
III	431906 transcript:SPCC306.11.1	- G
III	365747 transcript:SPCC594.06c.1	- CA
III	207507 transcript:SPCC1235.17.1	- C
II	154365 -	gene:SPN(G
II	154365 transcript:SPBC1683.07.1	CDS:SPB(GGG
II	113240 transcript:SPBC359.03c.1	- T
III	69609 transcript:SPCC757.11c.1	- G
I	43286 transcript:SPAC977.07c.1	CDS:SPA(CGT
I	3645128 transcript:SPAC8C9.03.1	- A
I	3645117 transcript:SPAC8C9.03.1	- C
III	1939467 -	gene:SPN(G
III	1939467 transcript:SPCC74.05.1	CDS:SPC(GGT
II	694252 transcript:SPBPJ4664.02.1	CDS:SPB(AAC
I	5321699 -	gene:SPN(C
I	4235601 transcript:SPAC1F7.08.1	- A
I	4140105 -	gene:SPN(A
I	3993810 transcript:SPAPB15E9.02c.1	- T
I	3993810 transcript:SPAPB15E9.06.1	- T
II	3856940 -	gene:SPN(A
II	3856937 -	gene:SPN(C
II	3856935 -	gene:SPN(C
II	3856934 -	gene:SPN(A
II	3856931 -	gene:SPN(G
II	3856930 -	gene:SPN(G
II	3856923 -	gene:SPN(GGAAGA
II	3856896 -	gene:SPN(A
I	3610417 -	gene:SPN(A
I	3610417 -	gene:SPN(A
I	3610417 transcript:SPAC17G6.11c.1	- A
II	3410437 -	gene:SPN(G
II	3380128 -	gene:SPN(C
II	3161493 transcript:SPBC609.01.1	- A
I	3033347 -	gene:SPN(C
I	2327021 -	gene:SPN(C
I	2327021 transcript:SPAC6C3.03c.1	- C
II	2204920 -	gene:SPN(G
II	2197587 transcript:SPBC17G9.13c.1	- C
II	2132606 transcript:SPBC1711.01c.1	CDS:SPB(AAA
II	2132604 transcript:SPBC1711.01c.1	CDS:SPB(T
II	2132601 transcript:SPBC1711.01c.1	CDS:SPB(C
III	2113205 -	gene:SPN(C
II	1964110 -	gene:SPN(C

I	1954162 -	gene:SPN(C
I	1954162 -	gene:SPN(C
I	1905516 transcript:SPAC110.05.1	- C
III	1674668 -	gene:SPN(A
III	1674667 -	gene:SPN(G
III	1674665 -	gene:SPN(C
III	1674664 -	gene:SPN(A
III	1674642 -	gene:SPN(C
I	1494950 transcript:SPAC5D6.10c.1	CDS:SPA(AGA
I	1494950 transcript:SPAC5D6.12.1	- G
III	1239230 transcript:SPCC645.06c.1	- G
I	1149920 transcript:SPAC56F8.13.1	CDS:SPA(A
I	1149920 transcript:SPAC56F8.14c.1	- A
III	970548 -	gene:SPN(C
III	717698 -	gene:SPN(TA
II	695620 transcript:SPBPJ4664.02.1	CDS:SPB(C
II	695615 transcript:SPBPJ4664.02.1	CDS:SPB(C
II	695611 transcript:SPBPJ4664.02.1	CDS:SPB(T
II	695473 transcript:SPBPJ4664.02.1	CDS:SPB(CTC
II	695466 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	695464 transcript:SPBPJ4664.02.1	CDS:SPB(TCT
II	695443 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	695442 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	694982 transcript:SPBPJ4664.02.1	CDS:SPB(TCA
II	693169 transcript:SPBPJ4664.02.1	CDS:SPB(CTG
II	670970 transcript:SPBC947.04.1	CDS:SPB(ACA
III	568658 -	gene:SPN(C
III	568658 transcript:SPCC1672.04c.1	- C
II	561064 -	gene:SPN(T
I	442783 transcript:SPAC23E2.01.1	- A
III	237023 transcript:SPCC1529.01.1	- A
III	208136 transcript:SPCC1235.17.1	- T
II	153578 transcript:SPBC1683.06c.1	- G
II	153578 transcript:SPBC1683.07.1	CDS:SPB(AGC
I	4514505 transcript:SPAC27D7.03c.1	- C
I	3993829 transcript:SPAPB15E9.02c.1	- G
I	3993829 transcript:SPAPB15E9.06.1	- G
I	3993828 transcript:SPAPB15E9.02c.1	- G
I	3993828 transcript:SPAPB15E9.06.1	- G
II	3856896 -	gene:SPN(A
I	3580034 -	gene:SPN(C
I	3580034 transcript:SPAC17A2.12.1	- C
I	3578659 -	gene:SPN(G
I	3578659 transcript:SPAC17A2.11.1	- G

II	3380153 -	gene:SPN(A
II	3161493 transcript:SPBC609.01.1	- A
I	3160024 transcript:SPAC3G9.11c.1	- A
I	3033365 -	gene:SPN(C
I	3033347 -	gene:SPN(C
I	2906433 transcript:SPAPYUK71.03c.1	CDS:SPA(TA
I	2525182 -	gene:SPN(G
I	2416348 transcript:SPAC6B12.04c.1	- C
I	2416348 transcript:SPAC6B12.18.1	- C
II	2197630 transcript:SPBC17G9.13c.1	- T
II	2197629 transcript:SPBC17G9.13c.1	- T
II	2197623 transcript:SPBC17G9.13c.1	- T
II	2197621 transcript:SPBC17G9.13c.1	- T
II	2197617 transcript:SPBC17G9.13c.1	- C
II	2197616 transcript:SPBC17G9.13c.1	- C
II	2197610 transcript:SPBC17G9.13c.1	- G
I	1955758 -	gene:SPN(T
I	1954162 -	gene:SPN(C
I	1954162 -	gene:SPN(C
I	1719470 transcript:SPAC664.09.1	- A
I	1719469 transcript:SPAC664.09.1	- G
III	1712983 transcript:SPCC191.05c.1	- G
III	1712983 transcript:SPCC191.06.1	- G
III	1702691 -	gene:SPN(C
III	1702691 transcript:SPCC417.15.1	- C
II	1684533 transcript:SPBC19C2.05.1	- C
III	1674618 -	gene:SPN(C
II	1389139 transcript:SPBC8D2.16c.1	- C
II	1171363 transcript:SPBC409.19c.1	- T
II	1171355 transcript:SPBC409.19c.1	- T
II	1045366 transcript:SPBC337.08c.1	CDS:SPB(CTT
II	1045363 transcript:SPBC337.08c.1	CDS:SPB(CAC
III	970548 -	gene:SPN(C
II	694291 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	694290 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	693100 transcript:SPBPJ4664.02.1	CDS:SPB(CAGTTCTACACCA,
II	692442 transcript:SPBPJ4664.02.1	CDS:SPB(AGT
II	670962 transcript:SPBC947.04.1	CDS:SPB(GCA
II	561064 -	gene:SPN(T
II	465514 transcript:SPBC428.11.1	- A
II	465513 transcript:SPBC428.11.1	- C
III	431932 transcript:SPCC306.11.1	- A
III	365747 transcript:SPCC594.06c.1	- CA
I	239258 -	gene:SPN(A

I	239258 -	gene:SPN(A
III	237048 transcript:SPCC1529.01.1	- G
III	69609 transcript:SPCC757.11c.1	- G

Table _seqchanges2_: Changes identified between all triplicates of P elf1Δ and one or both du

Altered Sequence	Original Amino Acid	New Amino Acid	Type of Change
C	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	ncRNA
AGT	S	S	SYN
TTG	L	L	SYN
GCT	V	A	NONSYN
TAC	Y	Y	SYN
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
CTT	-	-	INDEL
CTT	-	-	INDEL
CAAAAAAA	-	-	INDEL
A	-	-	INDEL
CT	-	-	INDEL
CT	-	-	INDEL
A	-	-	ncRNA
A	-	-	five_prime_UTR
ATTTTTTTTTTTTTTTT	-	-	INDEL
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
T	-	-	ncRNA
C	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAAG.-	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	three_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
ATA	K	I	NONSYN
AAT	K	N	NONSYN
TAG	K	*	NONSYN
AGG	K	R	NONSYN
T	-	-	five_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL

CAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
T	-	-	ncRNA
T	-	-	five_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
A	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
A	-	-	ncRNA
A	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	ncRNA
T	-	-	ncRNA
T	-	-	five_prime_UTR
T	-	-	three_prime_UTR
GTTTTTTT	-	-	INDEL
AAT	N	N	SYN
CTG	L	L	SYN
GTT	L	V	NONSYN
ACT	S	T	NONSYN
TCA	S	S	SYN
CCG	P	P	SYN
CTT	L	L	SYN
CTTTTTTTTTTTCCTTTTTTTTTTTTTT-	-	-	INDEL
GAAAAAAAAAA	-	-	INDEL
T	-	-	three_prime_UTR
A	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	ncRNA
A	-	-	three_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	three_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR

A	-	-	five_prime_UTR
T	-	-	three_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTCAATTTTTTT]-	-	-	INDEL
GA	-	-	INDEL
ATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT]-	-	-	INDEL
ATTTTTTTTTTTTTTTTTTTT	-	-	INDEL
GTTTTTTTCTTTTTTCTTTTTTTTTTTTTT]-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTT	-	-	INDEL
A	-	-	five_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
CAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
GTC	D	V	NONSYN
A	-	-	three_prime_UTR
GAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
CTTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
ATTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTT	-	-	INDEL
A	-	-	three_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
T	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
T	-	-	five_prime_UTR
AGT	S	S	SYN
A	-	-	five_prime_UTR
AAC	S	N	NONSYN
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
A	-	-	INDEL
A	-	-	INDEL
AGTTAGTC	-	-	INDEL

AGTTAGTC	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
ACATACCAT	-	-	INDEL
ACATACCAT	-	-	INDEL
GAA	-	-	INDEL
GAA	-	-	INDEL
GGTC	-	-	INDEL
GGTC	-	-	INDEL
C	-	-	five_prime_UTR
C	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
TAAAAAAAAAAAAAAAAAAGAAAAAAAAA-	-	-	INDEL
TAAAAAAAAAAAAAAAAAAGAAAAAAAAA-	-	-	INDEL
T	-	-	five_prime_UTR
TTG	L	L	SYN
GCT	V	A	NONSYN
GCT	A	A	SYN
T	-	-	ncRNA
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
A	-	-	INDEL
GTTCTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
ATTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
C	-	-	INDEL
ATTTTTTTTTTTTTTTTTCTTTTTTTTTTTI-	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
CTTTTTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	INDEL
A	-	-	three_prime_UTR
CAAAAAAAAAAAAAA	-	-	INDEL

T	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
AAA	T	K	NONSYN
A	-	-	three_prime_UTR
CTTTTTTTTTTTT	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
TAAAAAAAAAAAAAAAAAATAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
CTTTTTTTTTTTTTTTTGT	-	-	INDEL
GTAAAAAAAAAAAAAAAAAAAAAACTTGAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	three_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	INDEL
ATTTTTTTTTTTTTTT	-	-	INDEL
TTT	Y	F	NONSYN
A	-	-	five_prime_UTR
A	-	-	intron
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
TGC	F	C	NONSYN
G	-	-	three_prime_UTR
C	-	-	INDEL
C	-	-	INDEL
CT	-	-	INDEL
CT	-	-	INDEL
CGT	L	R	NONSYN
G	-	-	three_prime_UTR
ATA	K	I	NONSYN
AAT	K	N	NONSYN
TAG	K	*	NONSYN

AGG	K	R	NONSYN
T	-	-	three_prime_UTR
TA	-	-	INDEL
TA	-	-	INDEL
TCA	T	S	NONSYN
G	-	-	INDEL
G	-	-	INDEL
G	-	-	INDEL
AGT	S	S	SYN
ACT	S	T	NONSYN
TCA	A	S	NONSYN
GAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
AATAT,AATATAT	-	-	INDEL
AATAT,AATATAT	-	-	INDEL
GTGTATTGAAGTTAATCCTACCGATCGCA-	-	-	INDEL
C	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
A	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTTTI-	-	-	INDEL
GT,GTTTTTTTTTTTTTTTTTTTTTTTTATTTTTTTI-	-	-	INDEL
T	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	INDEL
G	-	-	three_prime_UTR
T	-	-	three_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTTTI-	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
ATTTTTTTT	-	-	INDEL
T	-	-	INDEL

GA	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTT	-	-	INDEL
CT,CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
ATTTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
ATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	five_prime_UTR
AAC	N	N	SYN
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	five_prime_UTR
GAA	K	E	NONSYN
TAA	-	-	INDEL
CCA	-	-	INDEL
T	-	-	five_prime_UTR
CTTTTTTT	-	-	INDEL
GAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	ncRNA
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
A	-	-	ncRNA
A	-	-	five_prime_UTR
CTA	L	L	SYN
CAT	H	H	SYN
TTTATGTC	-	-	INDEL
CGT	G	R	NONSYN
ATTTTT	-	-	INDEL
ATTTTT	-	-	INDEL
ATTTTT	-	-	INDEL
T	-	-	INDEL
T	-	-	INDEL
T	-	-	INDEL
C	-	-	three_prime_UTR
T	-	-	three_prime_UTR
CTC	L	L	SYN

C	-	-	INDEL
ACT	S	T	NONSYN
TCA	S	S	SYN
CCG	P	P	SYN
AGT	S	S	SYN
CTT	L	L	SYN
ACG	T	T	SYN
CGC	P	R	NONSYN
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTI-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTI-	-	-	INDEL
T	-	-	ncRNA
ATTTTTTTTTTTTT	-	-	INDEL
T	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	five_prime_UTR
GAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
AGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTI-	-	-	INDEL
T	-	-	three_prime_UTR
TAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAA/-	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAA/-	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAA/-	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAA/-	-	-	INDEL
GAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAA	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTATTTTTTTTI-	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
A	-	-	ncRNA
A	-	-	ncRNA
A	-	-	five_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	five_prime_UTR
T	-	-	INDEL
T	-	-	INDEL

T	-	-	ncRNA
T	-	-	five_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	ncRNA
GGGGGGCTTTTTTTTCTTTTTTTTTTTTTTTT	-	-	INDEL
TTTTA	-	-	INDEL
TTTTA	-	-	INDEL
A	-	-	five_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	five_prime_UTR
A	-	-	three_prime_UTR
A	-	-	ncRNA
A	-	-	three_prime_UTR
T	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
CTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	INDEL
A	-	-	ncRNA
CTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	five_prime_UTR
A	-	-	INDEL
A	-	-	INDEL
ACG	T	T	SYN
A	-	-	ncRNA
TCC	T	S	NONSYN
TTC	Y	F	NONSYN
A	-	-	ncRNA
TTA	L	L	SYN
CTT	P	L	NONSYN
A	-	-	ncRNA
CTT	L	L	SYN
TTT	I	F	NONSYN
A	-	-	ncRNA
TTT	L	F	NONSYN
TTT	S	F	NONSYN
T	-	-	INDEL

ACT	S	T	NONSYN
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
AAT	-	-	INDEL
AAT	-	-	INDEL
A	-	-	ncRNA
A	-	-	five_prime_UTR
T	-	-	three_prime_UTR
T	-	-	five_prime_UTR
GAC	D	D	SYN
C	-	-	INDEL
ATTTTTTTTTTTTTTTTATTTTTTTTTTTTTT-	-	-	INDEL
GAAAAAAAA	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
G	-	-	INDEL
ATTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
T	-	-	ncRNA
T	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
ATTT	-	-	INDEL
T	-	-	five_prime_UTR
C	-	-	three_prime_UTR
T	-	-	ncRNA
CTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
ATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
CTTTTTTTTTTTTAATTTT	-	-	INDEL
CTTTTTTTTTTTTAATTTT	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAAGAAAAA.-	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL

CAAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
TGT	R	C	NONSYN
C	-	-	INDEL
A	-	-	ncRNA
CTTTTTTTTTTTTTTTTGTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
CAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	ncRNA
A	-	-	ncRNA
CTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
A	-	-	three_prime_UTR
T	-	-	three_prime_UTR
GTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
GTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
GTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
TGT	G	C	NONSYN
GTTTTTTT	-	-	INDEL
AAT	N	N	SYN
T	-	-	INDEL
T	-	-	INDEL
T	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	ncRNA
A	-	-	three_prime_UTR
A	-	-	five_prime_UTR
AAC	S	N	NONSYN
GT,GTTTTTTT	-	-	INDEL
A,GAAAAAAAAAAAAAAAAAAAAAAAAA-	-	-	INDEL
A,GAAAAAAAAAAAAAAAAAAAAAAAAA-	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAA.-	-	-	INDEL
A	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	five_prime_UTR
A	-	-	ncRNA
A	-	-	ncRNA
A	-	-	five_prime_UTR

T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	five_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	three_prime_UTR
ATTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
GTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	INDEL
T	-	-	INDEL
T	-	-	INDEL
T	-	-	ncRNA
ATTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTT	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	ncRNA
A	-	-	three_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
T	-	-	five_prime_UTR
A	-	-	ncRNA
CTTTTTTTTTTTTTTTTTTTTTATCGTTTT	-	-	INDEL
T	-	-	ncRNA
A	-	-	INDEL
AAA	R	K	NONSYN
A	-	-	five_prime_UTR
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
CAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
TAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
A	-	-	five_prime_UTR
C	-	-	INDEL
GCT	T	A	NONSYN
TGT	Y	C	NONSYN
TAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL

T	-	-	ncRNA
T	-	-	three_prime_UTR
T	-	-	three_prime_UTR
C,AA	-	-	INDEL
A	-	-	three_prime_UTR
C	-	-	ncRNA
GGC	G	G	SYN
TAAAAAAAAAAAAAAAAAAAAAATTAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
TGT	R	C	NONSYN
T	-	-	three_prime_UTR
CTTTTTTTT	-	-	INDEL
A	-	-	ncRNA
GAT	G	D	NONSYN
AAT	N	N	SYN
T	-	-	ncRNA
T	-	-	five_prime_UTR
T	-	-	ncRNA
TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
G	-	-	INDEL
ATTTTTTTT	-	-	INDEL
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	five_prime_UTR
GTTTTTTTTTTTTTTTTTTCCTTTCTTAAAT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTT	-	-	INDEL
ATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTT	-	-	INDEL
A	-	-	ncRNA
A	-	-	five_prime_UTR
A	-	-	ncRNA
CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAA	K	E	NONSYN
TAA	-	-	INDEL
CCA	-	-	INDEL
CT	-	-	INDEL
CTTTTTTT	-	-	INDEL

CAAAAAAAAAAAAA	-	-	INDEL
CAAAAAAAAAAAAA	-	-	INDEL
T	-	-	three_prime_UTR
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
T	-	-	ncRNA
A	-	-	ncRNA
AAA	R	K	NONSYN
A	-	-	five_prime_UTR
A	-	-	three_prime_UTR
ACCCAAAAAAAAAAAAACAAAAAAAAA/-	-	-	INDEL
ACCCAAAAAAAAAAAAACAAAAAAAAA/-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
T	-	-	INDEL
CACATCCACACCAATTACTAGTTCAACTG-	-	-	INDEL
CAACTGCTT	-	-	INDEL
TTCTACACCAATTACTA	-	-	INDEL
CTG	L	L	SYN
ACT	S	T	NONSYN
TCA	S	S	SYN
AGA	S	R	NONSYN
ACT	S	T	NONSYN
CCA	S	P	NONSYN
CTT	L	L	SYN
ACG	T	T	SYN
CTTTTTTTTTTTTTTTTTTTTTTTTAATTTT-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTAATTTT-	-	-	INDEL
TAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/-	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
G	-	-	three_prime_UTR
A	-	-	five_prime_UTR
AAC	S	N	NONSYN
CAAA	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
ATTTTTTTTTTTTTTTTTTTTTTTTTTTT-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTATTTT-	-	-	INDEL
CTTTTTTTTTTTTTTTTTTTTTTTTATTTT-	-	-	INDEL
T	-	-	ncRNA
T	-	-	three_prime_UTR

ATTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
ATTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
ATTTTTTTTTTTTT	-	-	INDEL
CCTTTTTTTTTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTT	-	-	INDEL
T	-	-	INDEL
T	-	-	ncRNA
CTTTTTTTTTTTTTTTTTTATTTATTTTTTTT	-	-	INDEL
CTTTTTTTTTTTTTTTTTTATTTATTTTTTTT	-	-	INDEL
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
A	-	-	five_prime_UTR
G	-	-	ncRNA
CAAAAAAAAAAA	-	-	INDEL
CAAAAAAAAAAA	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
GAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
GAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	ncRNA
A	-	-	three_prime_UTR
A	-	-	three_prime_UTR
CTTTTTT	-	-	INDEL
CT	-	-	INDEL
TAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR
CTA	L	L	SYN
CAT	H	H	SYN
CTTTTTTTTTTTTTTTTTTTTTTTT	-	-	INDEL
AGA	S	R	NONSYN
ACT	S	T	NONSYN
C	-	-	INDEL
ACT	S	T	NONSYN
GTA	A	V	NONSYN
TAAAAAAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
T	-	-	five_prime_UTR
T	-	-	five_prime_UTR
T	-	-	three_prime_UTR
C,AA	-	-	INDEL
T	-	-	ncRNA

T	-	-	ncRNA
GAAAAAAAAAAAAAAAAAAAAA	-	-	INDEL
A	-	-	three_prime_UTR

plicates of S elf1Δ strains.

Compared Strains

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

P (A) vs. S (A1a)

[illegible]

[illegible]

1 (A) vs. 3 (AZd)

[illegible]

1 (A) vs. 3 (A3a)

[illegible]

[illegible]

[illegible]

$$= (-) \cdot (-) = (+) \quad (-) \cdot (-) = (+)$$

[illegible]

[illegible]

$$1 - (\frac{1}{2})^n \text{ vs. } 2 - (\frac{1}{2})^{n-1}$$

[illegible]

[illegible]

P (B) vs. S (B2b)

P (B) vs. S (B2b)

P (B) vs. S (B2b)

Chromosome	Position	Gene ID	Coding/Exon ID	Original Sequence
II	413473	transcript:SPBC106.18.1	-	A
II	413474	transcript:SPBC106.18.1	-	C
II	465486	transcript:SPBC428.11.1	-	C
III	1302685	transcript:SPCC1322.08.1	-	C
II	1389165	transcript:SPBC8D2.16c.1	-	A
III	1529703	transcript:SPCC584.01c.1	-	G
I	2327021	transcript:SPAC6C3.03c.1	-	C
I	3160028	transcript:SPAC3G9.11c.1	-	G
I	3160028	transcript:SPAC3G9.11c.1	-	G
I	3160028	transcript:SPAC3G9.11c.1	-	G
I	3160036	transcript:SPAC3G9.11c.1	-	G
I	3160036	transcript:SPAC3G9.11c.1	-	G
I	3160037	transcript:SPAC3G9.11c.1	-	A
I	3160037	transcript:SPAC3G9.11c.1	-	A
I	3160038	transcript:SPAC3G9.11c.1	-	C
I	3160038	transcript:SPAC3G9.11c.1	-	C
I	3160041	transcript:SPAC3G9.11c.1	-	G
I	3160041	transcript:SPAC3G9.11c.1	-	G
I	3160042	transcript:SPAC3G9.11c.1	-	C
I	3160042	transcript:SPAC3G9.11c.1	-	C
I	3477396	transcript:SPAC328.02.1	-	CA
III	180262	transcript:SPCC1235.03.1	CDS:SPCC1235.03.1:pep	CCGATC'
I	3477396	transcript:SPAC328.02.1	-	CA
I	3645117	transcript:SPAC8C9.03.1	-	C
II	3883700	transcript:SPBC211.05.1	-	A
II	3883700	transcript:SPBC211.06.1	-	A
I	3993810	transcript:SPAPB15E9.02c.1	-	T
I	3993810	transcript:SPAPB15E9.06.1	-	T
II	4165206	transcript:SPBC14F5.06.1	CDS:SPBC14F5.06.1:pep	G
III	1939467	-	gene:SPNCRNA.1245	G
II	1952886	-	gene:SPNCRNA.1481	A
I	2327021	-	gene:SPNCRNA.813	C
III	1939467	transcript:SPCC74.05.1	CDS:SPCC74.05.1:pep	GGT
II	692301	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	GTT
II	692301	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	GTT
II	670961	transcript:SPBC947.04.1	CDS:SPBC947.04.1:pep	GCA
II	1045183	transcript:SPBC337.08c.1	CDS:SPBC337.08c.1:pep	GAT
II	692303	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	CTG
II	692303	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	CTG
II	694252	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	AAC
II	693499	transcript:SPBPJ4664.02.1	CDS:SPBPJ4664.02.1:pep	AGC

II	670967	transcript:SPBC947.04.1	CDS:SPBC947.04.1:pep	TAT
I	1905516	transcript:SPAC110.05.1	-	C
I	3645128	transcript:SPAC8C9.03.1	-	A

Altered Sequenc e	Original Amino Acid	New Amino Acid	Type of Change	Compared Strains
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
T	-	-	five_prime_UTR	P (B) vs. S (B1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
A	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
A	-	-	five_prime_UTR	P (B) vs. S (B1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A2 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A1 a and b)
T	-	-	five_prime_UTR	P (A) vs. S (A3 a and b)
C	-	-	INDEL	P (A) vs. S (A1 a and b)
C	-	-	INDEL	P (B) vs. S (B1 a and b)
C	-	-	INDEL	P (A) vs. S (A3 a and b)
CTTTTTT	-	-	INDEL	P (B) vs. S (B2 a and b)
AAT	-	-	INDEL	P (B) vs. S (B1 a and b)
AAT	-	-	INDEL	P (B) vs. S (B1 a and b)
TAAAAA	-	-	INDEL	P (A) vs. S (A2 a and b)
TAAAAA	-	-	INDEL	P (A) vs. S (A2 a and b)
GTGTAT	-	-	INDEL	P (A) vs. S (A3 a and b)
A	-	-	ncRNA	P (B) vs. S (B2 a and b)
T	-	-	ncRNA	P (A) vs. S (A1 a and b)
A	-	-	ncRNA	P (B) vs. S (B1 a and b)
GAT	G	D	NONSYN	P (B) vs. S (B2 a and b)
GCT	V	A	NONSYN	P (A) vs. S (A1 a and b)
GCT	V	A	NONSYN	P (A) vs. S (A2 a and b)
GCT	A	A	SYN	P (A) vs. S (A2 a and b)
GAC	D	D	SYN	P (B) vs. S (B1 a and b)
TTG	L	L	SYN	P (A) vs. S (A1 a and b)
TTG	L	L	SYN	P (A) vs. S (A2 a and b)
AAT	N	N	SYN	P (B) vs. S (B2 a and b)
AGT	S	S	SYN	P (A) vs. S (A1 a and b)

TAC	Y	Y	SYN	P (A) vs. S (A1 a and b)
T	-	-	three_prime_UTR	P (B) vs. S (B1 a and b)
T	-	-	three_prime_UTR	P (B) vs. S (B2 a and b)

Chromosome	Position	Gene ID	gene name
I	3477396	transcript:SPAC328.02.1	dbl4
III	180262	transcript:SPCC1235.03.1	cue2
I	3477396	transcript:SPAC328.02.1	dbl4
I	3645117	transcript:SPAC8C9.03.1	cgs1
II	3883700	transcript:SPBC211.05.1	sap10
II	3883700	transcript:SPBC211.06.1	sap10
I	3993810	transcript:SPAPB15E9.02c.1	dubious
I	3993810	transcript:SPAPB15E9.06.1	dubious
II	4165206	transcript:SPBC14F5.06.1	rli1
III	1939467	transcript:SPCC74.05.1	rpl2702
II	692301	transcript:SPBPJ4664.02.1	unkown glycoprotein
II	692301	transcript:SPBPJ4664.02.1	unkown glycoprotein

Coding/Exon ID	Original Sequenc e	Altered Sequenc e	Original Amino Acid	New Amino Acid	Type of Change
-	CA	C	-	-	INDEL
CDS:SPCC1235.03.1:pep	CCGATC	C	-	-	INDEL
-	CA	C	-	-	INDEL
-	C	CTTTTTT	-	-	INDEL
-	A	AAT	-	-	INDEL
-	A	AAT	-	-	INDEL
-	T	TAAAAA	-	-	INDEL
-	T	TAAAAA	-	-	INDEL
CDS:SPBC14F5.06.1:pep	G	GTGTAT	-	-	INDEL
CDS:SPCC74.05.1:pep	GGT	GAT	G	D	NONSYN
CDS:SPBPJ4664.02.1:pep	GTT	GCT	V	A	NONSYN
CDS:SPBPJ4664.02.1:pep	GTT	GCT	V	A	NONSYN

Compared Strains

P (A) vs. S (A1 a and b)

P (B) vs. S (B1 a and b)

P (A) vs. S (A3 a and b)

P (B) vs. S (B2 a and b)

P (B) vs. S (B1 a and b)

P (B) vs. S (B1 a and b)

P (A) vs. S (A2 a and b)

P (A) vs. S (A2 a and b)

P (A) vs. S (A3 a and b)

P (B) vs. S (B2 a and b)

P (A) vs. S (A1 a and b)

P (A) vs. S (A2 a and b)

Chromosome	Position	Gene ID	
II	4165206	transcript:SPBC14F5.06.1	rli1
III	180262	transcript:SPCC1235.03.1	cue2
III	1939467	transcript:SPCC74.05.1	rpl2702
II	692301	transcript:SPBPJ4664.02.1	unknown glycoprotein
II	692301	transcript:SPBPJ4664.02.1	unknown glycoprotein

Coding/Exon ID	Original Sequence	Altered Sequence	Original Amino Acid	New Amino Acid
CDS:SPBC14F5.06.1:pep	G	GTGTATTGAA -	-	-
CDS:SPCC1235.03.1:pep	CCGATCTCTTGCTATG	C	-	-
CDS:SPCC74.05.1:pep	GGT	GAT	G	D
CDS:SPBPJ4664.02.1:pep	GTT	GCT	V	A
CDS:SPBPJ4664.02.1:pep	GTT	GCT	V	A

Type of**Change Compared Strains**


INDEL P (A) vs. S (A3 a and b)

INDEL P (B) vs. S (B1 a and b)


NONSYN P (B) vs. S (B2 a and b)

NONSYN P (A) vs. S (A1 a and b)


NONSYN P (A) vs. S (A2 a and b)





Click here to access/download
Supplemental Coding Files
fastq_to_vcf.sh



Click here to access/download
Supplemental Coding Files
vcfprocess.sh



Click here to access/download
Supplemental Coding Files
variant_characterize.py





Click here to access/download
Supplemental Coding Files
all.list





Click here to access/download
Supplemental Coding Files
all.list.filter.000100






Click here to access/download
Supplemental Coding Files
all.list.filter.000110







Click here to access/download
Supplemental Coding Files
all.list.filter.000111





Click here to access/download
Supplemental Coding Files
parental1.1.raw.vcf.gz.tbi





[Click here to access/download](#)

Supplemental Coding Files

PARENTAL1.1_2_3.v.MUTANT1.1_2_3.list

